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Adeno-associated virus (AAV) is a useful gene delivery tool for clinical and 
basic research applications. Since its discovery nearly 60 years ago, it has 
become a popular vector because of its small size and low immunogenicity. 
However, natural tissue tropisms are limited and frequently not useful. Past work 
modifying the capsid has been limited by structural constraints and a lack of 
modularity. I aimed to address this problem by creating a modular retargeting 
system in which the AAV capsid can be rapidly retargeted to any given antigen 
without newly mutating capsid proteins. I characterized AAV-antibody composites 
produced by incorporating a small DNA binding domain into one of the AAV 
capsid proteins and using chemical conjugation to attach the paired DNA 
sequence to an antibody. I demonstrated that these antibody-AAV conjugates 
are capable of infecting cells via the antibody-antigen interaction in immortalized 
and primary cells. Additionally, I created six capsid variants incorporating small 
targeting scaffolds into each AAV capsid protein. These variants will enable 
future researchers to select variants from scaffold libraries in vivo, making more 
specific, better targeting moieties.  
Using these retargeted vectors, I worked with colleagues to target prostate 
tumors in vivo and to deliver new payloads with therapeutic potential. A 
collaborator had recently developed an antibody against a prostate tumor stromal 
marker, fibroblast activation protein alpha (FAP). By conjugating this antibody to 
my modified virus, we were able to deliver a fluorescent marker specifically to the 
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tumor. Next, we plan to deliver therapeutic payloads to treat the tumor with 
minimal off-target effects. Additionally, I assisted in designing and testing a 
version of prime editor suitable for delivery by AAV. While the efficiency of this 
tool is still relatively low, it represents an important starting point for adaption of 
prime editor for use in vivo. In future work, we hope to use antibody-targeted 
AAV to deliver this and other editing reagents in murine disease models. 
Finally, to further investigate the landscape of the AAV capsid, we 
prepared a domain insertion library using a protocol recently developed by the 
lab. The results from this study will provide valuable information about the 
plasticity of the AAV capsid that can be used by future researchers to create new 
variants with added functionality.  
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Engineering adeno-associated virus for gene delivery 
 
After decades of basic research characterizing molecular pathologies of 
every disease from sickle cell anemia to glioblastoma, medicine is entering a new 
era of targeted therapy. With knowledge of the genetic basis of a disorder, it is 
possible to precisely correct the root cause, rather than just treat the symptoms. 
“Gene therapy” refers to delivery of a corrected copy of a diseased gene to an 
affected tissue1. There are many ways that an exogenous gene can be delivered 
to a tissue, broadly falling into viral and non-viral methods. While generally viewed 
as less immunogenic, non-viral delivery vehicles tend to be less efficient2. Adeno-
associated virus (AAV) has been the most clinically successful viral gene delivery 
vector. Two FDA-approved AAV-based gene therapy drugs are currently on the 
market, and many more are in phase II & III clinical trials1,3,4. AAV is a popular 
choice for gene therapy delivery because of its small size, low immunogenicity, 
and malleable genome 5. Since its discovery in the 1960s, AAV has grown from a 
contaminant to a valuable tool for therapy and research6. Decades of research 
have gone into characterizing its basic biology, engineering its protein capsid, and 
utilizing its genome to deliver a wide range of tools. 
 
Basic biology of AAV 
AAV is a non-enveloped virus with a 25nm diameter protein capsid7. The viral 
genome is 4.7kb single-stranded DNA (ssDNA) capped by hairpin-like inverted 
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terminal repeats (ITRs). There are three open reading frames encoding a total of 
eight proteins: four replication, three capsid, and one capsid assembly-activating 
protein. Although AAV has been studied for nearly 60 years, it wasn’t until 2010 
that capsid assembly-activating protein was discovered8. The two replication 
proteins, Rep68 and Rep78, are responsible for genome encapsulation and site-
specific genome integration on chromosome 199–11. Integration is key for AAV 
because it must remain latent until the host cells is infected with a helper virus, at 
which time AAV can replicate11. The AAV integration site (19q13.3-qter, AAVS1) 
is in the first exon of myosin binding subunit 5 of protein phosphatase 112. 
Integration rate is dependent upon multiplicity of infection (MOI), and does not 
occur consistently enough in vivo to be considered a sustainable integration 
method for engineered payloads12. AAVS1 has been used for integration of many 
other payloads, as it is known to be a safe harbor13. 
 The 60-subunit icosahedral capsid is formed from three proteins encoded by 
the Cap open reading frame. The three capsid proteins, called viral protein (VP) 
one, two, and three make up the virus in a ratio of 1:1:10, with VP3 composing the 
bulk of the capsid14,15. It is possible for capsids composed solely of VP3 to form, 
but they are non-infective due to loss of a phospholipase A2 domain encoded in 
the N-terminus of VP116,17. VP2, however, has been found completely 
unnecessary for formation of infectious particles17. This characteristic makes it a 
popular target for modification, as disruption of the structure is unlikely to make 
viral particles less infective and/or stable. 
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AAV is classified as a dependovirus because it requires co-infection with 
another virus, typically adenovirus or herpesvirus, to reproduce7. Co-infection of 
cells with two viruses is non-ideal for efficient recombinant production of AAV in 
research laboratories; the two can be difficult to separate, resulting in adenovirus-
contaminated stocks of AAV. To remedy this issue, the minimal components of 
adenovirus necessary for high-titer AAV production have been identified, and can 
be expressed on a transfected plasmid or by the virus-packaging cell. In current 
“helper-free” production of AAV, two adenoviral genes, E1a and E1b, are stably 
expressed by the packaging cell line, and an additional three necessary genes are 
transfected on a helper plasmid18,19.  
 
Structural characterization of AAV capsid 
Through x-ray crystallography, the structure of VP3 has been elucidated for 
many serotypes of AAV20–23. A model of the fully assembled capsid can be created 
from the monomer’s structure; recently, cryo-EM data has enabled direct imaging 
of the full capsid24. Some features are shared between serotypes; all have 2-, 3-, 
and 5-fold axes of symmetry with similar properties and dynamics25. Thermal 
stability and protease sensitivity vary wildly between capsids; it is unclear what 
functional or evolutionary implication this has26. 
When the virus is formed, the protein capsid assembles before the viral 
genome is packaged27,28. The precise mechanism of this process remains 
unknown, but it is thought to be mediated by the Rep protein recognizing a region 
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of the ssDNA genome called the D-sequence. Each genome has two D-
sequences, composed of the 20 innermost nucleotides of each ITR that remain 
linear when the remaining ITRs form T-shaped hairpins28,29. Much like the protein 
capsid, the AAV genome is incredibly information dense. In recombinant 
production, the entire genome apart from ITRs can be replaced with virtually any 
sequence of 4.7 kilobases. This size constraint can be limiting in clinical 
applications, resulting in studies to expand packaging capacity without hindering 
infectivity that have yielded minimal mixed success30–33. 
The different tropisms of AAV serotypes arise from the viral particles 
recognizing different cell surface molecules (Table 1.1). AAV-2, the most 
commonly clinically used vector primarily recognizes heparin sulfate proteoglycans 
via its heparin binding domain (HBD) present in a surface loop of all three capsid 
proteins34. AAV-2 also binds the secondary receptors beta-integrin and fibroblast 
growth factor receptor. Upon surface binding, the virus is endocytosed in a clathrin-
coated pit35. After entering the cell, the pH of the endocytic vesicle drops 
significantly, which causes the N-terminus of VP1 to be externalized. The 
phospholipase A2 domain breaks apart the vesicle, releasing the viral capsid36. It 
is still unclear whether the viral DNA reaches the nucleus before or after capsid 
disassembly37. Second-strand synthesis of the viral genome must occur before 




Engineering capsid proteins 
While many of its characteristics poise AAV to be an ideal gene delivery 
vector, the limited number of naturally occurring serotypes leave much room for 
improvement. The majority of AAV engineering has been focused on making 
viruses that infect different tissues than natural serotypes and reducing recognition 
by preexisting serum antibodies1,39–41. Increased tissue specificity for virtually any 
gene improves safety, with lower risk of off-target effects. Specificity is paramount 
for delivery of immunogenic or potentially harmful gene products such as Cas9 to 
correct a genomic mutation in a diseased tissue, or delivery of a 
therapeutic/apoptotic gene to a tumor. Retargeting efforts can be basically 
characterized into six categories and broadly defined as either structure-guided or 
library-based (Figure 1.2)42. 
 
Rational AAV capsid engineering 
Incorporation of a targeting moiety as a means of facilitating infection can be 
categorized as direct targeting. The first example of AAV being retargeted to infect 
a specific tissue dates to 1998, when the single chain variable fragment (scFv) of 
an anti-CD34 antibody was introduced to the N-terminus of AAV-2 VP2 as a 
chimeric protein (Figure 1.2)40. The engineered anti-CD34 AAV was shown to 
infect CD34+ cells several orders of magnitude more effectively than unmodified 
AAV2.  
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Taking this one step further, several groups have developed a series of 
directly targeted vectors based on designed ankryrin repeat proteins (DARPins) 
and affibodies. DARPins are a class of 14 kDa single domain proteins that can be 
selected to bind a target protein. They are advantageous because of their 
functional simplicity relative to derivatives of naturally occurring targeting 
molecules (i.e. scFv or nanobodies)43. Two anti-EGFR AAV-2 variants were 
created by incorporation of an anti-EGFR DARPin or affibody into the N-terminus 
of VP241. Both of these capsids infected cells over-expressing EGFR more 
effectively than AAV-2. Two engineered capsids containing DARPins targeting 
Her2 and EpCAM fused to the N-terminus of VP2 were described one year later44. 
These vectors were different in that they also contained a tag that allowed for 
affinity purification. Again, both effectively infected cells expressing the targeted 
receptor more effectively than unmodified AAV-2.  
The main critique of direct targeting is that it is a resource-intensive, high-risk 
endeavor42. Ultimately, the goal of any retargeted vector is clinical use, and the 
journey from bench to bedside is arduous. If the engineered capsid behaves 
unexpectedly at any point in pre-clinical or clinical trials, little can be done to modify 
it without starting the whole process over. For this reason, high-throughput, data-
driven engineering approaches have gained popularity in the last decade. 
 
Library-based AAV engineering 
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 While structure-guided, rational design can be a powerful method of altering 
viral capsid properties, library-based, structure-blind approaches have been used 
to create many new and differently functional variants. Some of the earliest AAV 
libraries were created by randomly recombining regions of different AAV serotypes 
to select for a vector with properties of each parent. An example of a created 
mosaic capsid is the creation of AAV-DJ, a serotype selected from a library of 
shuffled AAV-2, 4, 5, 8, and 9 capsids39. By applying a selection pressure, a capsid 
with very specific properties can be generated. AAV-DJ was selected to be 
minimally immunogenic with high liver tropism, properties that have led to it 
becoming one of the most commonly used synthetic serotypes. Further 
engineering has been done to improve its biodistribution45.  
A more modern example of capsid engineering is the creation of AAV-PHP-
B by the Gradinaru group46. Starting with AAV-9 as a base, a randomized seven 
amino acid loop (heptamer) was inserted into the surface of the capsid. By 
extracting AAV genomes from the mouse brain, the group was able to determine 
variants that could effectively cross the blood-brain-barrier (BBB). Synthetic 
evolution of a delivery vehicle faces major limitations in interspecies translation. 
While the AAV-PHP.B capsids work in the mouse line used for their selection (B6), 
a follow-up study found that they could not cross the BBB in other animal models, 
or even in other mouse lines47. The mechanism of transduction was characterized 
to be dependent upon Ly6A, a GPI-linked membrane protein which is absent in 
some mouse lines48,49. Notably, there is no known human homologue of Ly6A, 
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making it difficult to believe that AAV-PHP.B would be able to cross the blood-
brain-barrier in humans50. Given the volume of proteomic data for both model 
species and humans, it seems appropriate to create new capsid variants with a 
known mechanism of transduction.  
One major barrier to rational engineering of AAV has been the delicate 
constitution of the protein capsid. One group sought to map permissive spots in 
the capsid of AAV2 by inserting the coding sequence for mCherry at each position 
through VP351. Only one loop of the capsid could accommodate mCherry while still 
forming a functional virus, which is illustrative of the fragility of the capsid. No 
further domain insertion studies have been completed, either investigating AAV-2 
or other serotypes, but we anticipate that a more comprehensive study will be 
published in the next few years (see chapter 5).  
Mutational scanning has also been applied to AAV-2, revealing that even 
single point mutations can significantly change biodistribution and immunogenicity 
of the viral capsid52. Large, comprehensive screening studies such as this are 
beneficial in two ways: they provide directly useful structural insights, and they 
collect a bulk of information that can be further analyzed with different goals in 
mind. Recently, a massive library with a diversified 28 amino acid region of AAV-2 
was characterized, and data used to predict capsid viability using machine 
learning53. While there is no directly useful piece of information resulting from that 
work, the idea of first diversifying and screening variants in silico represents a 
 10 
powerful new tool. Other groups have applied machine learning to predict capsid 
properties from massive data sets54. 
 
Clinical gene therapy applications of AAV 
Beyond the bench, AAV is one of the most promising methods of clinical gene 
delivery. There are currently 145 ongoing clinical trials using AAV as a gene 
delivery vehicle registered with clinicaltrials.gov, five of which are treating cancer 
(March 11 2021). In late 2017, the FDA approved the first AAV-mediated 
therapeutic, a treatment for Leber congenital ameruosis type 255. This drug is an 
AAV2 capsid carrying the RPE65 gene and is administered as a sub-retinal 
injection.  
In the European Union, alipogene tiparvovec (Glybera), a mutated form of 
lipoprotein lipase delivered by AAV1, was approved for clinical use in 201256. 
Lipoprotein lipase deficiency (LPLD) is a disease characterized by high 
concentrations of fat droplets in the blood, which can lead to pancreatitis and 
development of type II diabetes. The drug was administered by multiple 
intramuscular injections and caused minimal side effects. Circulating lipids were 
significantly reduced in half of the patients two weeks post-injection, however in 
most patients, levels returned to pre-treatment within three months. This limited 
success, small patient population, and high cost led to the treatment being 
discontinued in 201857.  
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The most recently approved AAV-based therapeutic is onasemnogene 
abeparvovec (Zolgensma) to treat spinal muscular atrophy (SMA). SMA is caused 
by mutations of the gene survival motor neuron 1 (SMN1) and leads to death or 
permanent ventilation within the first 14 months of life58.  Zolgensma is an AAV9 
capsid encoding hSMN1 administered intravenously as one dose. Early results 
have shown striking improvement in symptoms, including an increase in probability 
of event-free survival from 20% in untreated to 100% in treated patients in a phase 
I trial58. Zolgensma is currently the most expensive medicine ever approved by the 
FDA at around $2 million per treatment spread out over 5 years 3. Gene therapies 
pose a unique challenge to pharmaceutical price models as one-and-done “cures”. 
Prior to its release, cost-effectiveness analysis of Zolgensma compared to 
standard of care treatment revealed that it would have been a cost-effective 
replacement if priced at $5 million or less4. While this garnered significant media 
attention as a high price for a single treatment, the lifetime benefit to patients and 
their families is undeniable. Gene therapy is ushering in a new era of 
pharmaceutical business models that will be fascinating to watch unfold. 
 
AAV as a delivery vector for editing reagents 
In an interview months before receiving the Nobel Prize for her discovery and 
characterization of CRISPR/Cas9, Jennifer Doudna cited the two primary 
challenges to the technology were delivery and DNA repair59. For safe in vivo use, 
it will be necessary to deliver editing reagents specifically to only cells requiring 
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editing. AAV is a top contender for delivery of editing reagents for the same 
reasons it is desirable for gene therapy2. Many editing therapeutics currently in 
clinical trials utilize ex vivo editing, where cells of interest are transduced with 
retroviral vectors before being returned to the patient60. The long-term safety of 
cells transduced with retroviruses is somewhat unknown. Recently, a clinical trial 
using a retrovirus to deliver editing reagents to patient-derived CD34+ 
hematopoietic stem cells for treatment of sickle cell disease was halted after two 
of the 14 patients treated developed leukemia61. Whether the retrovirus or some 
other factor caused the patients to develop cancer is unclear, but it raises serious 
concerns regardless.  
One of the main drawbacks of AAV for delivery of editing reagents is its 
genome size. Neither full-length S. pyogenes Cas9 nor APOEC-derived base 
editors fit in the genome with expression elements. Split versions of Cas9 and base 
editors have been developed to circumvent this issue62–64. Additionally, a smaller 
version of Cas9 from staphylococcus aureus has been characterized specifically 
for use with AAV65. Using these modified editors, high levels of phenotypic and 
genotypic modifications have been achieved in vivo64,66,67. Splitting cargo between 
two vectors can allow for greater control of expression, either by combinatorial 
targeting or by temporally regulating when each component is delivered68. While 
no AAV-based editing therapeutics are currently in clinical trials, that will likely 
change within the next decade2.  
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Viral gene therapy for treatment of cancers 
The idea of using infection to treat cancer— whether through directly infecting 
malignant cells or more broadly engaging and recruiting the immune system— is 
far from new, dating back to the mid-1800s69. Modern viral therapies for cancer 
broadly fall into three camps- using the virus’ natural lytic infection cycle to cause 
cell death, delivering an engineered lethal payload using the virus as a delivery 
vector, or recruiting the immune system70. Viral cancer gene therapy, delivering an 
engineered payload to tumor cells using a viral vector, is a promising treatment 
option that has been explored for multiple tumor types, including prostate cancer, 
glioma, and liver cancer71–73. The payload delivered varies, and is frequently either 
a suicide gene like HSV thymidine kinase (HSV-TK) or an immunostimulatory 
gene74. Different viruses have different utility in cancer therapy, with some more 
effectively recruiting the immune system, and others more effectively delivering 
therapeutic payloads. As with any gene therapy, one of the main hurdles is specific 
delivery to the tissue of interest. To address this problem, researchers have 
introduced regions that can be recognized by cancer-associated membrane 
markers such as integrins or CD13 into the viral capsid75,76. While effective, these 
markers are not applicable to all tumor types, so there is much work yet to be done 





Broad categories of AAV engineering. Adapted from42 AAV capsid engineering efforts 
can largely be categorized as structure-guided or library-based. Structure guided: 
Pseudotyping is replacing a capsid protein with one from a different serotype. Chemical 
adaptors can be added to an unmodified capsid post-production in cells. Direct 
targeting attaches targeting moieties (i.e. an antibody, scFv, nanobody, DARPin, etc.) to 
the capsid. Inverse targeting   Library-based: Mosaic capsids are selected from libraries 
composed of shuffled regions of multiple serotypes. Directed evolution iteratively 
selects from a library of capsid variants with diversity typically introduced randomly at 









Serotype Primary receptor In vivo tissue tropism 
AAV1 α2-3 and α2-6 N-linked 
sialic acid (SIA) 23,79 
Liver, muscle, airway epithelial cells, 
hematopoietic stem cells, CNS, 
pancreas 23,80–82 
AAV2 Heparin sulfate 
proteoglycan (HSPG), 
FGFR1, αVß5, laminin 
receptor (LamR)79,83,84   
CNS (limited), retina, muscle, lung, liver, 
hematopoietic stem cells, carotid 
arteries, intestinal epithelial cells, 
pancreatic beta cells, salivary glands, 
kidney 79,85 
AAV3 HGFR, HSPG79,86 Xenografted hepatocellular tumors, 
retina, lung, liver (limited) 82,86,87 
AAV4 α2-3 O-linked SIA 79 Kidney, brain, muscle, heart, lung 85 
AAV5 α2-6 N-linked SIA, PDGFR 
79,80 
Muscle, CNS, hematopoietic stem cells, 
retina, pancreas 80,82 
AAV6 α2-3 and α2-6 N-linked 
SIA, HSPG, EGFR 23,79 
Liver, muscle airway epithelial cells, 
CNS, heart 23,82,85 
AAV7 Unidentified 79,88 Liver, hind-limb skeletal muscle, testes 
82,85 
AAV8 LamR79 Liver, muscle, CNS, retina, pancreas 
82,89 
AAV9 N-linked galactose of SIA, 
integrins 79 
Heart, lung, testes, liver, hind-limb 
skeletal muscle, CNS 82,85 
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Adeno-associated virus (AAV) has emerged as a viral gene delivery vector 
that is safe in humans, able to infect both dividing and arrested cells, and drive 
long-term expression (> 6 months). Unfortunately, the naturally evolved properties 
of many AAV serotypes– including low cell type specificity and largely overlapping 
tropism – are mismatched to applications that require cell type-specific infection, 
such as neural circuit mapping or precision gene therapy. A variety of approaches 
to redirect AAV tropism exist, but there is still need for a universal solution for 
directing AAV tropism toward user-defined cellular receptors that does not require 
extensive case-by-case optimization and works with readily available components. 
Here, we report AAV engineering approaches that enable programmable receptor-
mediated gene delivery. First, we genetically encode small targeting scaffolds into 
a variable region of an AAV capsid, show that this redirects tropism toward the 
receptor recognized by these targeting scaffolds, and also renders this AAV variant 
resistant to neutralizing antibodies present in non-human primate serum. We then 
simplify retargeting of tropism by engineering the same variable loop to encode a 
HUH tag, which forms a covalent bond to single-stranded DNA oligos conjugated 
to store-bought antibodies. We demonstrate that retargeting this HUH-AAVs 
toward different receptors is as simple as 'arming' a pre-made non-infective AAV 
template with a different antibody in a conjugation process that uses widely 
available reagents and requires no optimization or extensive purification. 
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Composite antibody-AAV nanoparticles structurally separate tropism and payload 




Adeno-associated viruses (AAV) are members of the Parvoviridae family of 
ssDNA viruses that can infect both dividing and non-dividing cells90. AAVs are not 
associated with disease in humans9, and the general safety of AAVs for human 
gene therapy has been established in numerous clinical trials 91. AAVs are also 
well tolerated by laboratory animals 92. Together, these factors have contributed to 
the widespread use of AAVs in clinical and research applications, for example 
investigating and treating neurological, neurodegenerative, and neuropsychiatric 
disorders 93,94. Several natural AAV serotypes exist, which differ in viral capsid 
sequence 95. These sequence differences manifest as different properties of AAVs’ 
20-25 nm diameter icosahedral virion capsid, and much of the application-relevant 
biology of AAVs is derived from these properties. This includes capsid/receptor 
interactions, which drive tissue tropism96,97, and antigenicity and pre-existing 
immunity in mammals98,99. Cell surface glycans have been identified as the primary 
cell attachment receptor for most naturally occurring AAV serotypes (reviewed in 
97,100), and the recently identified AAV receptor (AAVR) is critical for endosomal 
entry35. Both are present on many cell types and therefore do not provide 
specificity of viral transduction beyond tissue specificity of different serotypes. The 
evolved properties of natural AAV serotypes are therefore a practical limitation for 
AAV-based gene delivery when cell type specificity is paramount, and when 
ectopic expression in off-target cell types is an undesirable safety risk7. 
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Pioneering studies have tackled this problem in several ways, all made 
possible by recombinant production methods for AAVs that only require a genetic 
payload flanked by two inverted terminal repeats (ITR) as the cis-element101. All 
other elements, including the cap gene, which encodes the three viral AAV capsid 
proteins VP1–3, can be provided in trans (Figure 1a). 60 copies of these beta-
barrel capsid proteins at a ratio of 1:1:18 form an icosahedral virus shell 30. VP1 is 
essential for viral particle infectivity16,102, VP2 is a redundant and nonessential 
protein17, and VP3 is the most abundant capsid protein. One line of research has 
attempted to change AAV serotype tropism by resurrecting ancient serotypes 103 
or repeated mutagenesis and shuffling of highly similar capsid genes21. One capsid 
gene shuffling experiment, using AAV-2, -8, and -9 as input, resulted in AAV-DJ, 
which shows superior infectivity in culture and biodistribution predominantly limited 
to the liver39.  
Another approach focused on the addition of short peptides in various 
capsid regions. From scanning mutagenesis studies25,51 and analysis of crystal 
structures of AAV capsids (e.g.20,104) a map of variable regions (VR) has emerged 
(reviewed in105). Best known is VR VIII (Figure 1b, Figure S1) a region that contains 
a heparin binding domain (HBD) critical for the heparin sulfate directed tropism of 
AAV2. Insertion of a 14 amino acid integrin-targeting peptide, L14, was among the 
first demonstrations that capsid tropism could be rationally retargeted toward a 
user-specific cell type104. Inserting random peptides into this loop to create a library 
of AAV variants is called viral display, and this method can be used to select AAV 
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capsid modifications that redirect AAV tropism toward, for example, cancer cells 
and endothelial cells106,107. Viral display was recently combined with in vivo 
biopanning into a more efficient directed evolution approach to select from a 
randomized AAV capsid library variants with specific tissue tropism108. Another 
viral display study created AAV-PHP.B, which efficiently crosses the blood brain 
barrier after intravenous injection46 in some mice strains109–111 and rats111,112. The 
inability of AAV-PHP.B to cross the blood-brain-barrier in genetic backgrounds of 
mice that lack the GPI-anchored cell surface protein LY6A47–49, and the mixed 
result of using AAV-PHP.B in non-human primates (severe toxicity at high 
doses47,113, lack of CNS tropism114) are cautionary notes. They highlight the 
complex and often unknown link between genetic variation of capsid genes and 
the selected phenotypes in directed evolution approaches, which may result in 
inadvertent optimization for undesired traits. 
A third approach to redirect AAV tropism is to add larger targeting scaffolds, 
most often to the N-terminus of VP2. This first worked to include a single chain 
antibody fragment against CD3440, and later for adding an CX3CL1 chemokine 
binding domain, the human hormone leptin, and even GFP (30kDa)17,115. The 
same approach was recently adopted to insert into VP2 a designed ankyrin repeat 
(DARPin)44,116,117 or an Affibody41, which directed virus tropism toward human 
endothelial growth factor receptors expressing cells. Unfortunately, modification 
on VP2’s N-terminus usually lowers the efficiency of VP2 incorporation into the 
capsid, increases the fraction of capsid that are empty (i.e. do not contain a genetic 
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payload), and the modified N-terminus can be trapped inside the viral capsid17,25,40. 
A variation on the theme of introducing specific targeting scaffolds into AAV 
capsids is the addition of an S. aureus protein A derived immunoglobulin binding 
domain (Z34C) into VR VIII77. This allowed subsequent coupling to antibodies 
against β1 integrin, CD117, or CXCR4, and redirected AAV tropism toward cell 
lines expressing these cell surface receptors. It is worth noting that the interaction 
between Z34C is a non-covalent, albeit high affinity, interaction. The dissociation 
rate constant is sufficiently high (~3x10-2 s-1 )118 that in an in vivo setting, it is a real 
possibility that Z34C-AAV-coupled antibodies are swapped out for endogenous 
antibody, which could lead to significant loss of infectivity or off-target infection. 
More recently, the addition of a split-intein domain the N-terminus of VP2 allowed 
covalent linkage of targeting ligands (including single chain antibodies (scFVs) and 
DARPins) to AAV119. However, this requires production and purification of targeting 
ligand/split-intein fusion proteins. 
Thus, while a variety of approaches to redirect AAV tropism exist, many require 
the repeated engineering capsid proteins (viral display, targeting scaffold 
insertions). Those that take a platform approach, form non-covalent adducts that 
limit biologic stability (e.g., AAVs displaying antibody targeting scaffolds) or require 
custom-made targeting ligands (e.g., intein-scFV fusions). There is still need for a 
universal solution for directing AAV tropism toward user-defined cellular receptors, 
and in turn cell types and tissues, that does not require extensive case-by-case 
optimization and works with readily available components. 
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In this study, we combine the strategies of previous studies to simplify retargeting 
of an engineered AAV variant. After validating an understudied AAV surface loop 
for insertion of small targeting scaffolds, we introduce into the same loop of the 
viral capsid a HUH tag. HUH tags are domains that form covalent bonds to single-
stranded (ss) DNA in a sequence specific fashion120. If these ssDNAs are 
conjugated to antibodies, we can form covalent antibody-AAV composites whose 
tropism is determined by the antigen-specificity of the linked antibody. We 
demonstrate that retargeting antibody-AAV composites toward different receptors 
is as simple as 'arming' a pre-made AAV template with different store-bought 
antibodies in a 30-minute reaction that requires no optimization or extensive 
purification. Composite AAV nanoparticles structurally separate tropism and 




Methods & Materials 
 
Construction of separate VP expression plasmids: 
All primers were designed using NEBaseChanger or NEBuilder. The CDS of all 
plasmids were verified by Sanger sequencing. Backbone integrity of all DNA 
preparations was confirmed by analytical digest.  
pCMV-cap was created by subcloning the cap open reading frame of AAV-DJ 
into a pcDNA5 backbone. The heparin binding domain (amino acids Arg587-
Arg590) was mutated to an HA tag (amino acid sequence YPYDVPDY) or a 6xHIS 
tag using NEB Q5 site-directed mutagenesis. To create plasmids individually 
expressing each VP, the start codons of the other two VPs were individually 
mutated using NEB Q5 mutagenesis: Met1Lys to knock out expression of VP1, 
Thr138Ala to knock out expression of VP2, and Met203Lys, Met211Lys, and 
Met235Lys to knock out expression of VP3. We found that it was necessary to 
mutagenize all three VP3 start codons to fully ablate expression. Using these 
mutations, we created staging plasmid pCMV-VP1ΔHBD>HA/6xHIS, pCMV-
VP2ΔHBD>HA/6xHIS, and pCMV-VP3ΔHBD>HA/6xHIS. Coding sequences for 
an anti-GFP nanobody (gift of Sivaraj Sivaramakrishnan), Gp258, and mMobA49 
were inserted, adding a (GGGGS)2 flexible linker on either side, into staging 




Production of modified viruses: 
AAV was packaged using established a helper-free production protocol by the 
UMN Viral Core. Briefly, AAV293 cells at 60% confluence were transfected with 
600 μg of DNA (viral shuttle vector encoding the payload, helper plasmid, rep/cap 
plasmids at 1:1:1 ratio) using polyethyleneimine. 24 hours after transfection, media 
was changed and cells were checked for fluorescent protein expression (when 
applicable) to confirm transfection. 72 hours after transfection, cells were detached 
and pelleted. Viral particles were released from producer cells by repeated 
freeze/thaw cycles in the presence of Benzonase (100 units). Crude lysates were 
cleared by centrifugation and further purified using sucrose gradients.  
Viral particles in the supernatant were titered using qPCR with WPRE-, GFP-, or 
tdTomato- specific primers. Kanamycin-specific primers were used to confirm 
absence of plasmid DNA after Benzonase treatment. 
The pAAV-CAG::tdTomato (codon diversified) shuttle vector was a gift from 
Edward Boyden (Addgene plasmid # 59462). The pAAV-CAG::GFP shuttle vector 
was a gift from Edward Boyden (Addgene plasmid # 37825).  
 
Western Blotting: 
2x1011 genome copies (g.c.) of each virus was denatured by heating to 95 C for 
5 minutes and run on SDS-PAGE. For paired antibody blots, the same reaction 
was split between two wells to yield an identically treated replicates for each 
antibody (B1 or HA.11). After staining with primary antibody (B1 or HA.11, see 
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Supplemental Table 2.2), blots were treated with anti-mouse horseradish-
peroxidase coupled secondary antibody, and visualized using ECL reagent. Blots 
were imaged using an Amersham Imager UV600.  
 
Virus Pulldown assays: 
For pulldown with streptavidin as the affinity matrix, approximately 1x10 g.c. of 
VP1- or VP2-mMobA-AAV was reacted with 1 nmole of biotinylated mMobA-
specific ssDNA in HUH reaction buffer (1:20 salmon sperm DNA, 1 mM MgCl2) for 
30 minutes at 37 degC. 50 μL of magnetic streptavidin beads were pelleted using 
a strong magnet and washed three times with 300 μL wash/binding buffer (0.5 M 
NaCl, 1 mM EDTA, 20 mM TrisHCl pH 7.5) to remove storage buffer. Oligo-
conjugated virus was bound to streptavidin beads for 10 minutes at RT with gentle 
agitation. Beads were washed three times with 300 μL wash/binding buffer. Beads 
were suspended in 100 μL wash/binding buffer with virus still bound and treated 
with proteinase K to extract viral genomes, as it is was not feasible to elute from 
the streptavidin. Beads were pelleted and supernatant was processed using Zymo 
Clean and Concentrator 5 kit prior to qPCR. qPCR was used to measure the 
number of viral genome copies retained by streptavidin beads. 
For pulldown with GFP as the affinity matrix, 150 μL of of magnetic streptavidin 
beads were pelleted using a strong magnet and washed three times with 300 μL 
of wash/binding buffer. 800 pmoles of a biotinylated superfolder GFP 
(recombinantly produced) were bound to washed beads at room temperature. The 
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beads were then washed with wash/binding buffer to remove unbound GFP. 
Separately, approximately 1x1010 g.c. of a VP2-mMobA virus was reacted with an 
anti-GFP antibody as previously described. For nanobody-AAV GFP pulldowns, 
virus was not treated prior to binding to beads. Anti-GFP virus was then incubated 
with GFP-streptavidin beads for 10 minutes at room temperature with gentle 
mixing. Beads were washed twice with wash/binding buffer and resuspended in 
100 μL buffer for treatment with proteinase K and benzonase to extract vector 
genomes for qPCR.  
 
Nanobody infection of HEK293-FT: 
HEK293-FT cells were plated on growth factor-depleted matrigel in a 24-well cell 
culture plate and reverse transfected with pCAG-GFP-GPI53 or a control plasmid 
(pATT, a gift from David Savage, Addgene plasmid # 79770). 24 hours after 
transfection, media was removed and cells were washed with 500 μL DMEM. Cells 
were incubated with DMEM and virus at a total volume of 240 μL for one hour at 
37 degC, after which 1 mL D10 cell maintenance media (DMEM, 10% w/v fetal 
bovine serum (FBS), 1% w/v sodium pyruvate, 1% w/v penicillin/streptomycin) was 
added on top of DMEM/virus. 48 hours after infection, cells were analyzed by 
fluorescent microscopy and flow cytometry. For neutralization assay, viruses were 
incubated in media with a given percentage of serum at 37 degC for 30 minutes 
before addition to cells. Culture medium was removed and cells were washed with 
DMEM before addition of serum/virus. 24 hours after infection, virus/serum was 
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replaced with unmodified D10. 48 hours after infection, cells were analyzed by 
fluorescent microscopy and flow cytometry. 
 
Gp2 infection of HEK293 expressing hIR: 
HEK293-hIR/GFP and HEK293-eGFP cells were a gift from Douglas Yee 58. 
Each cell line was plated on growth factor-depleted matrigel in a 24-well plate. 24 
hours after plating, media was removed and cells were washed with 500 μl DMEM. 
Cells were incubated with DMEM and virus (VP2-Gp2IR-AAV) at a total volume of 
240 μl for one hour at 37 C, after which 1 mL D10 was added on top of DMEM/virus. 
48 hours after infection, cells were analyzed by fluorescent microscopy and flow 
cytometry. 
 
Conjugation of HUH-AAV to antibodies:  
Antibodies (Supplemental Table 2.2) were conjugated to HPLC-purified ssDNA 
(CCA GTT TCT CGA AGA GAA ACC GGT AAG TGC ACC CTC CCT GAT GA - 
AmMO) using the Innova Biosciences Thunderlink Plus kit according to 
manufacturer instructions. Antibody and DNA were combined to an anticipated 
ratio of 3:1 DNA:antibody. Conjugation efficiency was determined via reducing 
SDS-PAGE. Average ratio of oligo:antibody was calculated by quantifying intensity 
of each band using ImageJ (release 1.52r). For GFP antibody, experimental 
DNA:antibody ratio was 2.29, for EGFR antibody 1.83, for CD7 1.40. It was not 
determined for L1CAM. 
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AAV Composite assembly: 
HUH-AAV in PBS with 10% glycerol was incubated in 1:20 salmon sperm DNA, 
0.2 M MgCl2, and 10 pmoles antibody-oligo for 30 minutes at 37 degC. Antibody-
AAV was applied to cells immediately after composite formation.  
 
GFP antibody-AAV infection of HEK293-FT:  
HEK293-FT cells were plated and transfected to express GFP-GPI as for 
nanobody infection assay. 24 hours after transfection, media was replaced with 
200 μl D10. Conjugated anti-GFP-AAV or control conjugated virus was applied to 
each well in 200 μl D10. 24 hours after infection, 1 ml D10 was added on to each 
well. 48 hours after infection, cells were analyzed by fluorescent microscopy and 
flow cytometry. 
 
EGFR antibody-AAV infection of U251 MG: 
U-251 MG cells were plated at 20% confluence on growth factor-depleted 
matrigel in a 24-well plate. 24 hours after plating, cells were treated with 
conjugated anti-EGFR-AAV or control conjugated virus in 200 μl D10. 48 hours 





CD7 antibody-AAV infection of Jurkat:  
Jurkat cells were cultured in RPMI-1480 with 10% w/v FBS and 1% w/v 
penicillin/streptomycin for several passages after thawing to acclimate cells to 
antibiotic. For infection assay, 1x105 cells were seeded into each well of a 96-well 
treated culture plate in 200 μl media. Anti-CD7-AAV was added to each well. 24 
hours after infection, 100 μl media was added and cells were mixed. 48 hours after 
infection, cells were moved to a 24-well plate and 200 μl media was added. 72 
hours after infection, cells were analyzed for transgene and CD7 expression using 
flow cytometry. 
 
L1CAM antibody-AAV infection of Primary Hippocampal Neuron/Glia Co-Culture 
All animal procedures were in accordance with the National Institute of Health 
Guide for the care and use of laboratory animals and approved by the University 
of Minnesota Institutional Animal Care and Use Committee (Protocol #1803-
35718A). Hippocampal regions from CD-1-022 mice (Charles River Laboratory) 
postnatal day 0 − 1 were isolated and digested with papain (100 units in Hanks 
balanced salt solution supplemented with 35 mM glucose, 1 mM Kynurenic acid, 
0.3 mg/ml L-Cysteine and 10 mM MgCl2) for 6 − 8 minutes. Cell suspension was 
washed with Ovomucoid trypsin inhibitor (10 mg/ml), washed three times with 1 
mL of plating media (MEM, 10% w/v fetal bovine serum, 0.5% w/v glucose, 10 mM 
HEPES, 2 mM L-glutamine, 0.5 mg/ml holo-transferrin, 25 μg/ml insulin, B27 
supplement, buffered to pH 7.4 with NaOH). The tissue was then mechanically 
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dissociated by triturating through P1000 plastic pipette tips, and settled by 
gravitation. Dissociated neurons and glia in the supernatant were plated on 
Matrigel-coated 24 well glass bottom plates at approximately 50,000 cells per well 
and maintained in plating medium. Two days after plating, anti-L1CAM-AAV was 
added to each well. 
 
Immunohistochemistry 
Five days after infection, cells were fixed with 2% formaldehyde, washed with 
PBS, and permeabilized with 1% Triton-100 in PBS at room temperature. Fixed 
neurons and glia co-cultures were incubated in blocking buffer (PBS, 0.1% Triton-
100, 15% FBS) for 30 minutes at room temperature. Fixed cells were stained with 
primary antibodies (GFAP, clone 2.2B10; NeuN, clone A-EPR12763, see 
Supplemental Table 2.2), diluted to 1:500 in blocking buffer, for 1 hour at room 
temperature, and washed twice with 0.1% Triton-100 in 2x PBS. Secondary 
antibodies (GFAP, anti-rat Alexa Fluor 350; NeuN, anti-rabbit Alexa Fluor 700, see 
Supplemental Table 2.2) 1:500 diluted in blocking were added and incubated for 
1 hour at room temperature. After washing twice with 0.1% Triton-100 in 1xPBS 
and twice with 1xPBS, fixed cells were imaged immediately. 
 
Wide-field Fluorescent microscopy: 
For unfixed cells, 48 hours after infection, media was removed and replaced with 
200 μL Tyrode buffer (125mM NaCl, 2mM KCl, 3mM CaCl2, 1mM MgCl2, 10mM 
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HEPES, 30mM glucose, pH 7.3). Nuclei were stained with NucBlue Live Cell stain 
(Thermofisher) for 30 minutes at 37 degC before imaging. NucBlue and Alexa 
Fluor 350 were excited at 395±25 nm, with a 409 nm dichroic, and recorded at 409 
nm longpass. GFP was excited at 470±24 nm, 495 dichroic, and recorded at 
525±24 nm. tdTomato was excited at 575±25 nm, 596 nm dichroic, and recorded 
at 609±54 nm. AlexaFluor 700 was excited at 635±18 nm, with a 652 nm dichroic, 
and recorded at 680±42 nm. Images were processed using ImageJ (release 1.52r). 
The Cell Counter plugin was used to determine neuron/glia infection ratios.  
 
Flow cytometry analysis:  
Adherent cells were detached using Accutase. All cell types (adherent and non-
adherent) were then centrifuged at 400 x g for 3 minutes, washed with 1 mL Tyrode 
buffer once, resuspended in 300 μl FACS buffer (2% of FBS, 0.1% NaN3, 1xPBS), 
and passed through a 35 μm nylon filter tubes. 
Samples were run on a BD Fortessa X-20 flow cytometer. GFP was excited with 
a 488nm laser and recorded with on a 525±50 nm filter. tdTomato was excited with 
a 561nm laser and recorded on a 585±15 nm filter. APC was excited with a 640nm 
laser and recorded on 670±30 nm filter. Events were gated on side-scattering area 
and forward-scattering area and subsequently forward-scattering area and width 
to separate out live, single cells. Samples were down-sampled to collect 20,000 




 While many studies have focused on engineering VR VIII, VR IV (Figure 
2.1b) has emerged as an alternative loop amenable to engineering51,104. We 
constructed cap variants of AAV-DJ39, in which VR VIII was mutated to include an 
HA or 6xHIS tag (AAV-DJΔHBD>HA/6xHIS), which in previous work removed 
natural tropism of  AAV241,116,121. We then introduced an anti-GFP nanobody (nb, 
size: 13.2 kDa,122) into VR IV (amino acid position Thr456). Nanobodies consist of 
only a single domain that, like antibodies, specifically bind a specific antigen123. 
Since all three AAV capsid proteins (VP1–3) are produced from different open 
reading frames of the cap gene, we generated a set of trans-complementation 
plasmids with the required mutations of alternate start codons, so we could 
express each VP independently (Figure 2.1c, Supplemental Figure 2.2). 
Western blot (performed for all VP-nb-AAV) and pulldown assays with GFP-
conjugated magnetic beads (VP2-nb-AAV and VP3-nb-AAV only) qualitatively 
confirmed incorporation of nanobody fusions with all three VPs in rAAV 
(Supplemental Figure 2.3a,c). Nanobody-modified AAVs could be produced to 
titers that are comparable to wildtype AAV-DJ (~5x1010 and ~4x1011 genome 
copies (g.c.)/μl, respectively, Supplemental Table 2.1). Note that for VP3-nb-AAV 
production, we had to co-transfect trans-complementing plasmid encoding for both 
nb-modified VP3 and unmodified VP3 to achieve acceptable titers. Since VP3 is 
the most abundant capsid protein (44 copies/capsid), we interpret this as 
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nanobody insertion having a destabilizing effect that interferes with virus 
production when capsids are composed of mostly modified capsid proteins. 
We next assessed whether nanobody incorporation redirects AAV tropism toward 
the nanobody’s binding target. As a synthetic surface receptor, we expressed GPI-
anchored GFP124 on the extracellular membrane of HEK293 cells and infected 
these target cells with different virus preparations that all carried tdTomato driven 
from a strong and broadly active CAG promoter125 as the genetic payload. Overall, 
AAV-DJ was more infective at any tested multiplicity of infection (MOI), but 
nanobody-modified AAV infectivity was within the same order of magnitude 
(Figure2.2a-b). Interestingly, VP2-nb-AAV performed better than VP1- or VP3 
modified AAV. We currently do not know what mechanism underlies this difference 
in infectivity. Possible causes include that a fraction of virions lack nanobody 
modifications, that nanobody incorporation changes the ratio of empty and full 
capsid, or that nanobody/receptor interaction direct AAV to a different intracellular 
compartment after cellular uptake. Arguably, on-target selectivity is the most 
striking feature of nb-AAV. As expected, when cells where infected with wildtype 
AAV-DJ, transduction was indiscriminate in both GFP-positive and GFP-negative 
cells. Conversely, AAV-DJΔHBD>HA proved non-infective, as expected from 
removing the heparin binding domain that mediates AAV interaction with the cell. 
AAV capsids with nb-insertion in any capsid protein, on the other hand, 
preferentially infected GFP-positive cells. As a scoring function for on-target 
selectivity we calculated the ratio of on-target (GFP-GPI transfected) over off-
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target (control plasmid pATT transfected) cells. Selectivity for GFP-positive cells 
was noticeable already at low MOI (1,000 g.c. / cell) for VP2-nb (score 45.514.68) 
vs. AAV-DJ (0.810.29). At higher MOI (>1,000 g.c. / cell) VP1-nb and VP3-nb on-
target selectivity became apparent, as well. Interestingly, while peak on-target 
selectivity was similar for all nb-AAV variants, they peaked at different MOI. That 
selectivity dropped for all nb-AAV at the highest MOI test was driven by higher off-
target infection. Overall, these data suggest that VR IV is permissive to nanobody 
insertion, and that this insertion can redirect tropism toward the receptor target by 
that nanobody. While overall infectivity it reduced to some degree, high on-target 
specificity can be achieved at low MOI. 
 
We next tested whether nanobody-mediated targeting toward GFP as a synthetic 
cell surface receptor provides additional benefits in the forms of evading 
neutralizing antibodies. That the majority of the human population is sero-positive 
to most existing AAV serotypes126 is one of the most pressing concerns with 
potential AAV gene therapy7. Neutralizing antibodies are also an issue when using 
AAV on non-human primate neuroscience99. Neutralization mechanisms of 
antibodies vary and can include interference with primary receptor binding or post-
attachment steps (endosomal escape, conformational change in the capsid, etc.) 
80. When we compared transduction of HEK293 cells expressing cell surface GPI-
anchored GFP with either AAV-DJ or VP1-nb-AAV, we found that AAV-DJ 
transduction was decreased >20 fold in the presence of pooled rhesus macaque 
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serum (Figure 2.3). VP1-nb-AAV transduction, on the other hand, was unaffected 
even at the highest serum concentration tested (20%). This suggests not only that 
neutralizing antibodies were present in the rhesus macaque serum, but also that 
nanobody incorporation provides resistance to neutralization by these antibodies. 
Interestingly, AAV-DJ is the result of forced evolution in presence of pooled human 
antisera (purified human Ig (IVIG)), which provides strong negative selection 
pressure against AAV-2 epitopes, and AAV-DJ transduction efficiency had been 
found to be unaffected by presence IVIG39. We did not test VP2-nb- or VP3-nb-
AAV, but suspect that they are resistant to neutralization by serum as well. 
 
We next asked whether this kind of receptor-mediated infection could be 
extended to other targeting scaffolds. T7 gene 2 protein (Gp2) scaffolds are small 
(6 kDa) proteins domains with two solvent-exposed loops that can be mutated to 
generate a binding interface to arbitrary targets127. We incorporated into VR IV a 
Gp2 binding human insulin receptor (hIR128) with nanomolar affinity, creating 
Gp2IR-AAV variants. Similar to what we observed for nanobody-AAVs, modification 
of all three capsid proteins appeared tolerated when judged by virus production 
titers (7.6–9.6x1011 g.c./μl, Supplemental Table 2.1). To assess hIR-directed 
infection, we compared infection of hIR-overexpressing HEK293 and control 
HEK293 cells that only express a basal (endogenous) level of hIR128. While 
wildtype AAV-DJ indiscriminately infected both hIR-expressing and control cells, 
and tropism null AAV-DJΔHBD>HA infected neither, all Gp2-displaying AAV at any 
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MOI preferentially infected hIR-overexpressing cells (Figure 2.4). Importantly, 
when using Gp2IR-AAV, we observed greater specificity at lower MOI compared to 
AAV-DJ; at 1x104 g.c. / cell the ratio of on-target (hIR) to off-target (control 
HEK293) is >11-fold for VP2-Gp2 (p-value 0.0047, two sided Dunnett's-test for 
multiple comparison with AAV-DJ as the control). However, efficiency of this 
transduction was less than 5%. Conversely, at the highest MOI tested, while still 
significantly more selective than AAV-DJ, the selectivity ratio dropped to ~1.6 (p-
value 0.00227, 0.00019, and 0.00073 for VP1-, VP2-, and VP3-Gp2 two sided 
Dunnett's-test for multiple comparison with AAV-DJ, respectively) while 
transduction levels approaches 50%. The trade-off between transduction 
efficiency and on-target selectivity highlights multiplicity of infection is a critical 
parameter that may require optimization when on-target and off-target cell are 
defined only by differences in expression levels of the targeted receptor. Overall, 
our data nevertheless suggest that genetic insertion of targeting scaffolds into VR 
IV might be a general strategy to redirect AAV tropism. When combined with 
orthogonal approaches, such as cell-type specific promoters, this may provide an 
additional axis along which AAVs can be engineered to achieve cell-type specific 
infection. Our data is also compatible with a simple equilibrium model for virus 
entry in which infection efficiency depends on expression levels of the targeted 




While nb and Gp2 insertion into VR IV are well tolerated and redirect AAV 
infection toward their respective binding target, these require repeated genetic 
modification and production of viral particles whenever a new targeting scaffold is 
used. We reasoned that a generalizable method of linking new targeting scaffold 
to viral particles is achievable by inserting a universal adapter domain into the AAV 
capsid. Adapter-containing AAV can then be produced once, stored, and ‘armed’ 
with different targeting scaffolds as needed. One type of targeting scaffold that is 
of particular interest are antibodies. Over the past decades research and 
development in both industry and academic labs have resulted in a rich repertoire 
of characterized antibodies with well-understood receptor specificity and mature 
production pipelines 129,130. Monoclonal antibodies have emerged a class of 
therapeutic agents to numerous human diseases including cancer, auto-immune, 
and cardiovascular disorders. And leveraging these existing antibodies for re-
targeting AAV tropism might represent a new mode of action for these drugs. 
The principle of linking pre-produced AAV to targeting scaffolds has been 
previously advanced. Early work modifying VR VIII inserted a minimal Protein A 
Fc-binding domain into the AAV capsid77. However, the interaction between this 
domain and antibodies are non-covalent. Split-intein-mediated covalent 
attachment of targeting scaffold, on the other hand, requires custom production of 
components119. 
To establish a method of covalently linking store-bought antibodies to AAV on 
demand, we turned to the recently described HUH tags, which are small (10-30 
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kDa) and robustly form covalent bonds with short ssDNA in a sequence-specific 
fashion120. HUH domains are orthogonal and multiplexible; there is minimal overlap 
between sequences that each HUH domain recognizes and binds. We expected 
that by displaying a HUH domain on the AAV capsid, we could covalently attach 
ssDNA-conjugated antibodies to AAV particles in a programmable fashion (Figure 
2.5a). Modification of antibodies with ssDNA is a widely-adopted step in immuno-
PCR and within practical reach to most labs131. 
A set of trans-complementing plasmids allowed us to express individual capsid 
protein variants with a mMobA HUH tag (size 21 kDa) inserted in VR IV. To 
determine which HUH insertion in which capsid protein was functional, we reacted 
AAV particles with mMobA inserted into either VP1 (titer 1.37x1011 g.c./μl), VP2 
(titer 4.9x1011 g.c./μl), or VP3 (titer 1.5x108 g.c./μl) with a ssDNA oligo that 
contained the mMobA recognition sequences and that was also biotinylated. After 
pulldown with streptavidin beads, we determined presence of full AAV capsid by 
qPCR. While we did not recover any fully packaged viral particles when mMobA 
was inserted into VP3, we did recover particles for insertions into VP1 and VP2 
(Supplemental Figure 2.3c). In line with our results for nanobody-modified AAV 
and the lower production titer for VP3-mMobA (Supplemental Table 2.1), 
modification of VP3 appears to be less well tolerated. Alternative explanations for 
the lack of pulldown are that VP3-mMobA is not conformationally accessible to 
oligo conjugation (and therefore is not pulled down) or that insertion of mMobA 
results in mostly empty AAV particles (titers are measures by qPCR with genomic 
 41 
probes). Our titer data for VP1- and VP2-mMobA showed, however, that insertion 
of the mMobA HUH tag in the VR IV loop of VP1 or VP2 of AAV-DJ was tolerated. 
We qualitatively confirmed this for VP2 by Western blot and affinity pulldown 
(Supplemental Figure 2.3b-c). A more quantitative look at the Western Blots 
suggested that mMobA-modified VP2 is incorporated at a ratio that deviates from 
the expected 1:1:18 ratio of VP1:VP2:VP3. When using a pan-VP antibody (B1), 
the band corresponding to VP2-mMobA was very faint, and only with an antibody 
specific to the HA tag inserted into VR VIII of VP2-mMobA could we confirmed 
incorporation of the expected fusion capsid protein. Streptavidin-bead pulldown 
experiment in which the VP2-HUH-AAV was reacted with a mMobA specific oligo 
that also had was biotinylated similarly suggested that not every particle carried 
VP2-mMobA at wild type copy number; typically, ~30-40% of virus was retained. 
Despite the apparently low incorporation of VP2-mMobA, we reasoned that 
VP1/VP3-only capsid in which the heparin binding domain had been mutated 
would not contribute significantly to infection and went ahead with functional 
characterization of VP2-mMobA-AAV (referred to from here on as ‘HUH-AAV’) 
without any further enrichment of purification. 
 
To test whether HUH tags allow for on demand assembly of antibody-AAV 
composites, we conjugated an ssDNA oligo contain the mMobA’s recognition 
sequence to a store-bought GFP antibody (Supplemental Table 2.2) using widely 
available copper-free click chemistry (Supplemental Figure 2.4). Composites 
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between HUH-AAV (carrying CAG-tdTomato as payload) and ssDNA-mAb were 
formed by brief incubation under physiological conditions. Pulldown experiment 
with GFP-linked magnetic beads show that GFP antibodies are reacted to HUH-
AAV (Supplemental Figure 2.3c). We then applied anti-GFP-HUH-AAV 
composites to HEK293 expressing GFP-GPI without further purification. 48 hours 
after infection, cells were analyzed for expression of the viral transgene. As 
anticipated, cells expressing GFP-GPI treated with the full antibody-AAV 
composite expressed tdTomato, while fluorescence was much lower in cells not 
expressing GFP-GPI (Figure 2.5b-c). Omitting any one component of the 
composite (i.e. mMobA-specific ssDNA, antibody, GFP-GPI target, mMobA HUH 
tag) resulted low transduction indicating that only complete composites mediate 
receptor-specific infection. When compared to nanobody-modified AAV, we did 
notice slightly higher baseline of off-target infection with VP2-mMobA-AAV (~8% 
vs. 5% at 1x106 g.c./cell). Since off-target infection was least pronounced in 
negative controls without VP2-mMobA (i.e., VP1/3ΔHBD>HA, Figure 2.5c) we 
suspect that the biophysical properties of the mMobA domain itself contribute to 
non-specific infection. That relatively little expression was observed at lower MOI 
may in part be due to the relative short period of time that was allowed for onset of 
viral payload expression (48h) and the presence of unreacted free antibody that 
could interfere with anti-GFP-HUH-AAV attachment to surface-anchored GFP. 
Most likely, however, relative low infectivity is related to heterogeneity in the 
composition of the full antibody-AAV composites, which we suspect comes from 
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multiple sources. For one, VP2-mMobA fusion proteins may not incorporate into 
assembling AAV particles (as suggested by Western Blot, Supplemental Figure 
2.3b) or may decrease particle stability (although, we did not see a decrease in 
production titer, Supplemental Table 2.1). In both cases, HUH-AAV ready to react 
with ssDNA-conjugated AAV represent only a fraction of all AAV particles. HUH 
incorporation may also prevent encapsulation of the viral genome, in which case 
HUH-AAV particles are more likely to be empty and, while infective, non-
transducing. Again, this is a less likely scenario as we did not observe a decrease 
in production titer. Finally, mMobA reaction efficiency with its cognate ssDNA 
target is less than 100% efficient (as suggested by pulldown experiments with 
biotinylated mMobA-specific ssDNA, Supplemental Figure 2.3c). All of these 
inefficiencies can add up and lead to a mismatch between qPCR-determined titers 
(which measure full AAV particles and on which we based MOI) and the 
indeterminate titers of fully-assembled antibody-AAV composites that encapsulate 
a viral payload. Clearly, process improvements (removing unreacted antibody, 
enriching for HUH-containing AAV, etc.) could boost infectivity. However, even in 
light of the current limitations, our data demonstrate that incorporation of HUH tags 
into AAV capsids allows for covalent attachment of antibodies, and that these 
antibodies redirect tropism of antibody-AAV composites toward specific cellular 
receptors.  
To demonstrate ease of re-targeting to a new cell surface receptor, we next 
formed composites with HUH-AAV from the same batch used in the experiments 
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above, but now linked to an EGFR antibody or a CD7 antibody, both store-bought. 
Anti-EGFR-AAV composites infectivity was tested in U-251 MG cells, which are an 
immortalized glioblastoma cancer stem cell line that naturally expresses high 
levels of EGFR132 (Figure 2.6a). As before, when antibody was absent or present 
but not covalently linked to the AAV capsid, only minimal infection was observed. 
The full composite was about half as infectious as AAV-DJ. We also used Jurkat 
cells, an immortalized T cell line that naturally expresses high levels of CD7, for 
anti-CD7 AAV composites infection133 (Figure 2.6b). Interestingly, AAV-DJ show 
only marginal infection (10% at 1x107 g.c./cell) making this a good example for 
how generalizable receptor-mediated infection with antibody-AAV composites can 
be. As before, we found that mutations of the heparin binding domain (AAV-
DJΔHBD>HA) almost completely abolished infectivity even at high titer. Providing 
but not covalently linking an anti-CD7 antibody to the HUH-AAV also did not result 
in infectious particles beyond putative non-specific levels. Full anti-CD7-AAV 
composites, on the other hand, could achieve >80% infection at the highest MOI 
tested. Overall, these data suggest that HUH incorporation is a generalizable 
method to redirect AAV tropism toward any user-selected surface receptor in a 
programmable fashion. 
To assess whether receptor-mediated infection extends beyond synthetic targets 
and immortalized cell lines that express a cell surface receptor at relatively high 
levels, we turned to primary neuron hippocampal neuron cultures. Neuron cultures 
are prepared by enzymatic and physical dissociation of brain tissue from newborn 
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mice and are actually a co-culture of neurons (~70% of cells) and glia (~30% of 
cells). To develop a viral targeting strategy that can differentiate between neurons 
and glia by virtue of a cell surface marker expressed at native levels and without 
relying on a cell-type specific promoter we turned to L1CAM. L1CAM is an 
axonally-targeted protein that belong to a larger class of immunoglobulin-like cell 
adhesion molecules that mediate cell-to-cell recognition and are responsible to 
multiple aspect of neuronal development134. L1CAM is expressed on most neurons 
in the central nervous systems at the onset of differentiation, but is not expressed 
in glia cells. Using the same batch of tropism-null virus that we had used in the 
previous experiments, we formed anti-L1CAM-AAV composites. Composite virus 
carried tdTomato driven from the widely active CAG promoter. After two days in 
vitro, neuron cultures were infected, and after an additional 7 days fixed and 
stained for a neuronal marker (NeuN) and a glia marker (GFAP) (Figure 2.7a). 
Comparing immunohistochemistry from these experiments to controls (neuron 
culture infected with tropism-null HUH-AAV carrying CAG-tdTomato), we found 
that composite virus preferentially infected neurons by a large margin (Figure 
2.7b). Whereas in control experiments neurons and glia were infected to similar 
degree (ratio ~1), with anti-L1CAM-AAV composites neuron infection was ~7.5-
fold more likely. Overall, these data suggest that receptor-mediated viral gene 
delivery is possible with a mixture of on-target and off-target cells and without 




 We have demonstrated that AAV-DJ VR IV, which has been described in 
the context of fluorescent proteins insertion51, is amenable to insertion of targeting 
scaffolds (including nanobodies and phage protein scaffolds) and that these 
scaffolds redirect tropism toward their cognate receptors. Unlike VR VIII, which is 
often the target of viral display studies46, VR IV can tolerate large insertions (up to 
30kDa). Unlike modifications of the VP2 N-terminus, another previously described 
way to engineer AAV tropism41, there is little chance for the inserted targeting 
moiety to become trapped in the capsid interior. We showed that insertions can be 
made in capsid proteins all three capsid proteins independently, although 
modifications of VP1 & VP2 generally were better tolerated. An additional upside 
of selectively modifying VP1 is that if the modified capsid protein is not 
incorporated, the resulting viral particles will be non-infective. This is because VP1 
contains a phospholipase domain that is critical for efficient endosomal escape102. 
When we consider that VP3 is ~10-fold more abundant in the AAV capsids than 
VP1, it is tempting to raises the possibility of a single viral capsid carrying multiple 
targeting moieties with different copy numbers. However, we have observed that 
AAV with modifications of VP3 (nanobody, Gp2, or mMobA HUH) can only be 
produced at high titer when unmodified VP3 is expressed in trans. This supports 
the idea that having too many copies of targeting scaffolds per capsid impacts 
capsid assembly and/or stability which would result in a lower titer overall, or could 
increase the fraction of empty particles that are produced (which would also appear 
 47 
to lower the qPCR-determined titer). In addition, capsid engineering might 
introduce greater heterogeneity of recombinantly produced AAV particles. For 
example, not every AAV particle may incorporate a copy of an engineered capsid 
protein, which would manifest as apparently normal production titers but lower 
infectivity. Our Western blot and pulldown data do suggest that this is the case in 
our preparations, in particular for HUH-AAV. Further studies, ideally in several 
AAVs serotype, that quantitively assess the relationship between different capsid 
modifications, virus yield, stability, and function are required to better understand 
the tradeoff that are being made when AAVs are engineered in this fashion. This 
may help us to tailor targeting scaffold insertion strategies to maximize specificity 
of the engineered tropism while minimally impacting other viral properties. 
 Cell surface glycans and other co-receptors (often receptor tyrosine 
kinases) have been identified as the primary receptor cell attachment for 
AAVs96,100, while the AAV receptor (AAVR) is critical for endosomal entry35 that 
can occur through clathrin-dependent, clathrin-independent pathways, caveolar 
endocytosis, and others135. While usage of AAVR is conserved for most AAV 
serotype in primates, AAV can transduces at low level in the absence of AAVR, 
both in vitro and in vivo136. Together, this suggests that multiple uptake pathways 
exist for AAVs. An open question is whether viral uptake pathway preference is 
altered as a result of the introduced targeting scaffolds. It is conceivable that the 
introduction of targeting scaffolds simply switches the primary attachment step 
from glycans to the targeted receptor and that this interaction follows a simple 
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equilibrium model with targeting scaffold/receptor affinity determining probability of 
virus uptake. This would explain why tropism-retargeting maps directly to the 
receptor molecule recognized by the targeting scaffold added to the AAV capsid 
(e.g., GFP with anti-GFP-AAV, etc.) and why transduction efficiency is sensitive to 
surface receptor expression levels (e.g., hIR with Gp2IR-AAV). It is also possible 
that uptake mediated by this alternate receptor directs modified AAV variants into 
different endosomal compartments that have better microtubule-dependent 
trafficking to the nucleus or from which AAVs has an easier time to escape. This 
would explain how AAV composites can have higher transduction efficiency in cell 
lines that less permissive to wildtype AAV infection (e.g., Jurkats infected with 
AAV-DJ vs. anti-CD7-AAV). The apparent resistance to neutralizing antibodies 
that is provided by introduction of nanobody could also be explained by this 
mechanism. In addition to interfering with cell attachment, neutralizing antibodies 
against AAV can interfere with the cellular trafficking mechanism that lead to 
perinuclear accumulation nuclear uptake137. Utilizing different receptors, whose 
identity influences sorting of the endocytosed cargo138,139, may be a way to 
override the mistrafficking effects of neutralizing antibodies. 
Most importantly, we demonstrate that HUH tag adapter domains mediate 
covalent attachment of ssDNA-modified antibodies to AAV. By reusing the same 
batch of HUH-AAV to form AAV composites that infect different cell types, we 
further advance the previously proposed concept77,119 that adapter-containing 
AAVs can be produced once, bio-banked, and ‘armed’ with different targeting 
 49 
scaffolds as needed. This represents a significant improvement to other 
approaches that incorporate targeting scaffolds in the viral capsid through genetic 
engineering. They still require viral vector packaging for each new target, so the 
cost-savings that are achievable when the base capsid is re-used can be 
significant. Furthermore, re-usable tropism-null AAV technology paves the way for 
a generalized re-targeting method toward arbitrary cellular receptors. One way this 
might be achieved is to leverage the large diversity of existing antibodies. 
Extensive antibody discovery pipelines have been established in the last decade 
that supported the development of therapeutic antibodies and antibody-drug 
conjugates140. It is conceivable that being part of antibody-AAV composites 
represents another mode of action for these already developed and validated 
targeting scaffolds. In this respect, the ability to prepare AAV composites with 
targeting scaffolds that don’t have to be genetically engineered (e.g., adding a split-
intein) is tangible advantage of the approach presented here. The modification of 
antibodies with ssDNA is an established step in immuno-PCR and uses off-the-
shelf reagents and processes. Lastly, copper-free click chemistry can be applied 
to non-proteinaceous molecules as well. This means that other types of bio-
polymers (DNA, polyethers, polysaccharides, etc.) are in theory amenable to 
programmable HUH-mediated assembly with AAV. 
 Most importantly, structurally separating the two functions of AAVs 
(targeting and payload encapsulation) means that both functions can be 
engineered independently. For example, one could alter the immunogenic profile 
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of the tropism-null base capsid to increase efficacy of gene delivery in the presence 
of neutralizing antibodies7 without affecting the fidelity of the targeting mechanism. 
Improved versions of HUH tags can replace the ones we currently use, resulting 
in the next generation of HUH-AAV that exhibit higher coupling efficiency of the 
conjugated antibodies, improved capsid incorporation of the HUH-tag, a lower off-
target infection. Other methods of viral retargeting (specifically, viral display46, 
serotype reshuffling39, and related directed evolution approaches) are inherently 
limited in this respect because structural components that mediate both functions 
(i.e. the capsid proteins) are shared, which might result in adaptive conflict when 
the same structure/sequence cannot simultaneously satisfy different constraints or 
results in loss of a function that was not under selection pressure. 
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Supplementary Figure 2.1 
 
Alignment of AAV capsid proteins from different serotypes. Variable Regions 
(VR), the heparin binding domain (HBD), common loops are indicated by boxes.  
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Trans-complementation plasmids for production of AAV with modified 
capsid proteins. Line drawing represent pAAV-DJ rep and cap genes, with 
endogenous promoters (arrows), and introduced mutations (start codons, yellow; 
heparin binding domain replacement with a HA tag, green). The resulting gene 
products expressed from each rep/cap variant are shown below.  
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Supplementary Figure 2.3 
 
Western blot of nanobody- and HUH-modified capsids, and affinity pulldown 
of nanobody-  or mMobA-modified virus. a, Gradient-purified AAV capsid 
proteins, either wildtype AAV-DJ, or AAV-DJΔHBD>HA containing anti- GFP-
nanobody-modified VP1-, VP2-, or VP3 were separated by SDS-PAGE following 
Western Blot with the an anti-AAV antibody (clone B1). Capsid protein 
corresponding with each band, along with the predicted molecular weight, are 
shown. While the shift in molecular weight is noticeable for VP1-nb, VP2-nb and 
VP3-nb overlap with VP1 and VP2, respectively. Note that addition of the HA tag 
appears causes proteins to run slightly higher than their theoretical size and that 
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to produce VP3-nb, unmodified VP3 had to be expressed as well. * denotes non-
specific bands. b, Gradient-purified VP2-mMobA-AAV capsid proteins 
(composition: AAV-DJ-VP1/VP3ΔHBD>6xHIS and VP2ΔHBD>HA-mMobA) were 
separated by SDS-PAGE following Western Blot with the an anti-AAV antibody 
(clone B1) or anti-HA antibody (clone 16B12). Capsid protein corresponding with 
each band, along with the predicted molecular weight, are shown. * denotes non-
specific bands. c, Incorporation of nanobody or mMobA modified capsid protein 
was further investigated by affinity pulldown experiments with GFP-conjugated 
magnetic beads (to which anti-GFP-nb-AAV and anti-GFP-HUH-AAV bind) or 
Streptavidin-conjugated beads (bindingmMobA-AAV reacted with a biotionlylated 
mMobA-specific ssDNA oligo). Beads were washed, viral genomes were extracted 
from bead-bound capsids and analyzed using qPCR. Percent of affinity matrix-
retained virus, compared to input material, is shown.  
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Supplementary Figure 2.4 
 
 
Antibody conjugation with ssDNA oligo. anti-GFP IgG(a),anti-EGFR IgG (b), 
and anti-CD7 (c)conjugated to an HUH- specific oligo using a commercial copper-
free click chemistry kit. Conjugation was carried out per kit instructions to achieve 
a ratio of 3:1 oligo:antibody. Unreacted and conjugated antibody were analyzed 
using denaturing SDS-PAGE. Average ratio of oligo:antibody was calculated by 
quantifying intensity of each band using FIJI image software. Experimental 
oligo:antibody ratio was calculated to be 2.29 for anti-GFP, 1.83 for anti-EGFR, 
and 1.40 for anti-CD7.  
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Supplemental Table 2.1 
 
Virus Description Capsid Constructs 
Used 
Typical Titer GC/uL 
VP1-nanobody BP-00238, BP-00395 6.79x1010 
VP2-nanobody BP-00142, BP-00396 5.05x1010 
VP3-nanobody BP-00382, BP-00391, 
BP-00397 
4.54x1010 
VP1-Gp2 BP-00238, BP-00447 9.64x1011 
VP2-Gp2 BP-00142, BP-00448 7.88x1011 
VP3-Gp2 BP-00382, BP-00391, 
BP-00449 
7.63x1011 
VP1-mMobA BP-00238, BP-00398 1.37x1011 
VP2-mMobA BP-00142, BP-00437 8.40x1011 
VP3-mMoba BP-00382, BP-00391, 
BP-00438 
8.51x1011 
AAV-DJ pAAV-DJ 3.57x1011 
AAV-DJDHBD>HA/6xHis BP-00385, BP-00142 8.22x1011 
 
Typical titers for recombinantly produced AAV 
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Supplemental Table 2.2 
 
 
Antigen Clone Source Part 
Number 
Application 
GFP 9F9.F9 Abcam ab1218 Attached to 
virus 






48-0079-42 Attached to 
virus 






17-0079-42 Flow cytometry 
EGFR EGFR-PE ThermoFisher MA5-28544 Flow cytometry 
(not shown) 
AAV B1 ARP 03-61058 Western blot 




Polyclonal ThermoFisher 31430 Immuno-
histochemistry 
NeuN EPR12763 Abcam ab177487 Immuno-
histochemistry 
GFAP 2.2B10 ThermoFisher 13-0300 Immuno-
histochemistry 
Goat anti-rat IgG 
cross-adsorped 
secondary antibody, 
Alexa Fluor 350 
Polyclonal ThermoFisher A-21093 Immuno-
histochemistry 
Goat anti-Rabbit IgG 
cross-adsorbed 
secondary antibody, 
Alexa Fluor 700 
Polyclonal ThermoFisher A-21038 Immuno-
histochemistry 
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Preface 
Prime editing brings immense promise to correct a large number of human 
pathogenic mutations and enact diverse edit types without introducing widespread 
undesired editing events. Delivery of prime editors in vivo would enable such edits 
to be introduced in a clinical setting. The coding sequence for prime editor, 
however, is too large to fit within the size-constrained adeno-associated virus 
(AAV) genome. Herein, we describe a split Staphylococcus aureus prime editor 
capable of being delivered by dual AAVs. We characterize the editing ability of 
plasmid-based versions of an S. aureus prime editor in vitro at a variety of loci with 
diverse edit types. We investigate various split prime editor architectures and 
alternative dimerization domains. Finally, we demonstrate the capacity of prime 
editor to be co-delivered by dual AAVs in vitro. While editing rates are lower than 






Genome editing has brought incredible promise to correct or ameliorate 
previously untreatable genetically linked diseases such as Tay-Sachs disease or 
Phenylketonuria (PKU). The use of programmable nucleases such as CRISPR-
Cas9 that introduce a DNA double-stranded break (DSB) enables precise gene 
editing at a desired locus141,142. Traditionally, homology-directed repair (HDR) has 
been the only means to introduce precise nucleotide changes at a DSB via the 
supplementation of a donor DNA molecule encoding the changes. HDR, however, 
usually occurs less frequently than the circumstantially undesired non-homologous 
end joining (NHEJ) pathway143. To circumvent the NHEJ pathway, base editors 
were designed to change single bases in DNA without the need to create a DSB144. 
Base editors employ nickase Cas9s that have one of the nuclease domains 
mutated to prevent cleavage on one DNA strand. Base editors, as the name 
suggests, are limited to introducing transition point mutations (purine:purine or 
pyrimidine:pyrimidine), although recently C to G base editors have been 
characterized145,146. While NHEJ levels are low with base editors and high rates of 
precise editing can be achieved, the restraint on editing type and inability to edit 
specific bases within a window makes it not ideal for many desired precise genome 
editing applications. 
The latest advent in CRISPR genome editing technologies is prime editor, 
which is capable of introducing a wide change of precise modifications without the 
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need for DSB formation147. Like base editor, prime editor utilizes a Cas9 (H840A) 
nickase. A reverse transcriptase (RT) is tethered to the nickase while a prime 
editing guide RNA (pegRNA) contains a 3’ extension serving as both the genome 
hybridizing site (primer binding site; PBS) and the RT template encoding the 
desired edits. Prime editor cleaves the single strand of DNA, the PBS of the 
pegRNA hybridizes with the newly exposed ssDNA, and the RT synthesizes from 
the RT template. Flap resolution and DNA mismatch repair then allow for 
incorporation of the desired modification. Therefore, prime editing is theoretically 
able to make edits downstream of the nick site, termed the +1 site. Prime editor 
was shown to allow for edits ranging from codon changes to small insertions and 
deletions through encoding these modifications in the 3’ pegRNA extension147. 
Hypothetically, prime editor is capable of correcting close to 90% of human 
pathogenic mutations147. As with other types of genome editing technologies, 
however, in vivo targeting and delivery remains a large hurdle to overcome to 
achieve such a goal2. 
         Adeno-associated virus (AAV) is the most common in vivo delivery vehicle 
for gene editing reagents. AAV contains a single-stranded DNA (ssDNA) genome 
that can be replaced with transgenes of interest. The virus can target a wide range 
of tissue and cell types with a relatively low immunogenicity profile. AAV-mediated 
delivery of CRISPR-Cas has been successfully deployed to produce indels148, 
create chimeric T-cell receptors149, and generate large deletions67. Extensive 
engineering efforts have also modified the virus to enhance cell-specific delivery 
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or decrease immunogenicity1. A major constraint of AAV is the maximum size of 
its ssDNA genome, roughly 4.7 kb not including the two flanking inverted terminal 
repeats (ITRs)31. The conventional Cas9 originating from S. pyogenes (SpCas9) 
is 4.2 kb in size, allowing little space for necessary regulatory elements such as 
promoters and terminators and precludes encoding of a gRNA expression cassette 
in the same genome. To overcome this limitation, smaller orthologs of Cas9 such 
as from S. aureus (SaCas9) have been utilized65. The gene length of SaCas9 is 
approximately 1 kb shorter than SpCas9 allowing for more freedom in packaging 
in AAV. Another strategy to deliver full-length Cas proteins has been to split the 
protein into two AAV vectors to be co-delivered. This approach can take place on 
the DNA, RNA, or protein level (reviewed in 150). On the protein level, engineered 
split trans-splicing inteins can be co-opted essentially as dimerization domains to 
bring two halves of a split protein together 151. For base editor to be packaged and 
delivered by AAV, a split base editor, split intein system was used64,66. The two 
intein halves associate at low nM affinity and swiftly excise themselves out, leaving 
only a small scar. For both SpCas9 and SaCas9, various groups have identified 
numerous permissible split locations that allow the proteins to retain nearly full 
activity once recombined64,152. 
Prime editor was previously shown to be delivered ex vivo using a three-part 
lentivirus system to mouse primary cortical neurons147. This approach, however, is 
not broadly applicable in the clinic due to constraints on choice of cell type to edit. 
Ribonucleoprotein (RNP)-containing lentiviral particles have been used to 
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transiently deliver Cas9153, but the sheer size of prime editor protein (~250 kDa) 
makes it difficult to produce conventionally in E. coli and package. Ideally, AAV 
would be used to deliver prime editor. At ~6.4 kb, prime editor is too large to be 
encoded into a single AAV genome. Even when constituted as a split version, 
prime editor is unable to fit into two AAV genomes with the necessary regulatory 
elements and the pegRNA expression cassette. 
To address this size constraint issue, we developed a new version of prime 
editor using SaCas9(N580A) as the guided nickase. We demonstrate that S. 
aureus prime editor (SaPE) can also introduce targeted changes to a wide range 
of genomic loci from point mutations to larger deletions. We assessed three 
different split locations in concert with split intein and split NanoLuc approaches to 
reconstruct full-length, active protein. All versions of split SaPE were capable of 
inducing editing events, although they tended to be less efficient than the full-
length protein. The split version can be packaged into two standard size AAV 
genomes and be delivered in viral form in vitro. This work opens a potential avenue 




Materials and Methods 
 
Nucleotide and amino acid sequences 
 The following tables contain sequences for pegRNAs (Supplementary 
Table 3.1), sequencing primers (Supplementary Table 3.2), and proteins 
(Supplementary Table 3.3). All oligonucleotides were synthesized by Integrated 
DNA Technologies (IDT). 
  
Cloning and DNA assembly 
 All prime editor expression vectors were generated using NEBuilder HiFi 
DNA assembly (New England Biolabs; NEB). The pegRNA expression vectors 
were generated as described below from Addgene plasmid #132777 (Generously 
provided by David Liu). AAV expression vectors were generated using NEBuilder 
HiFi DNA assembly combined with standard restriction digestion of the AAV vector 
backbone pAAV-CAG-GFP containing standard AAV2 ITRs. The S. pyogenes 
prime editor expression vector was a gift from David Liu (Addgene #132775). S. 
aureus Cas9 was amplified from a vector courtesy of Feng Zhang (Addgene 
#61591). Q5 site directed mutagenesis (New England Biolabs) was used to 
generate the Npu (C1A) mutation. Assembly reactions were transformed into 
competent Stellar cells (Takara Bio). Plasmid DNA was purified either as minipreps 
(Qiagen) or maxipreps (Thermo Fisher). DNA concentration was quantified using 
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 The pegRNAs were cloned using a protocol adapted from the Liu lab147. 
These modifications were made to incorporate the S. aureus gRNA scaffold 
sequence and to add some streamlined features in regard to vector digestion and 
golden gate assembly cycling conditions. A detailed protocol is provided in 
Supplementary Note 3.1. For S. aureus pegRNAs, the annealing protospacer 
oligonucleotides were designed as such: Forward (CACC ...(G) (spacer 
sequence)... GTTTT) and reverse (TACTAAAAC …(reverse complement) (C)...). 
Add a G prior to spacer sequence if it doesn’t begin with a G (and corresponding 
C on the reverse oligonucleotide). The pegRNA 3’ extension annealing 
oligonucleotides were designed as such: Forward (GAGA …(RT template + 
PBS)...) and reverse (AAAA …(reverse complement)...). The phosphorylated 
scaffold oligonucleotides were: Forward (/5Phos/ 
agtactctggaaacagaatctactaaaacaaggcaaaatgc cgtgtttatctcgtcaacttgttggc) and 
reverse (/5Phos/ tctcgccaacaagtt 
gacgagataaacacggcattttgccttgttttagtagattctgtttccagag). Golden gate assembly 
was performed with 1 µl each of 1 µM stocks of these 3 annealed oligonucleotides, 
250 ng of pU6-pegRNA-RFP acceptor (Addgene #132777, courtesy of David Liu), 
1 U of BsaI-HFv2 (NEB), 1 U of T4 DNA ligase (NEB), and 1x T4 DNA ligase buffer 
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in 10 µl total volume. Reaction conditions were as follows: 10 cycles of 5 min at 37 
°C and 10 min at 16 °C followed by inactivation steps of 5 min at 55 °C and 5 min 
at 85 °C. 1 µl of the assembly reaction was transformed into competent Stellar 
cells. Non-red colonies were picked for subsequent DNA isolation. 
  
Cell culture 
 HEK-293T, U2-OS, HCT116, RPE1, and HEK-293 cells were cultured in 
DMEM (Corning) supplemented with 10% FBS (Gibco) and 0.5% 
penicillin/streptomycin (Gibco). Cells were incubated at 37°C in 5% CO2. Bxb1-
mediated recombination was used to generate the stable, single copy 
GFP(L202S)-2A-mKate2 HEK-293T cell line154. 
  
Plasmid transfection 
 Cells were seeded in a 48-well plate at 30,000 cells per well or in a 24-well 
plate at 60,000 cells per well. Approximately 24 hr post-seeding, cells were 
transfected using Lipofectamine 2000 (Invitrogen). A 1:1 molar ratio of prime editor 
to pegRNA vector was used (250:83 ng in 48-well plates or 500:167 ng in 24-well 
plates) according to the suggested manufacturer’s protocol. For split prime editor 
transfections, the total amount of prime editor vector was held constant. Cells were 
incubated for 72 hr post-transfection for all downstream analyses. 
  
Analysis of reversion of GFP L202S mutation 
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 Flow cytometry analysis was carried out on a BD Fortessa X-20 instrument 
at the University of Minnesota Flow Cytometry Resource. Cells were prepared by 
first washing the cells with PBS and detaching with Accutase (Sigma). Cells were 
gently pelleted, washed with ice-cold PBS, and resuspended in ice-cold PBS 
supplemented with 5% FBS. Data from 10,000 to 100,000 cells was collected using 
BD FACSDiva software and compiled using FlowJo (version 10.6). Cells were 
initially gated based on FSC-A and SSC-A (for live cells) and then gated on FSC-
W versus FSC-H (for single cells). The presence or lack of GFP expression was 
then evaluated (Supplementary Note 3.2).  
In separate experiments, live cell imaging was carried out on an Olympus 
IX83 inverted microscope equipped with an Andor iXon Ultra 888 EM-CCD. 
Fluorescence was provided by a Sola light engine (Lumencor). For 
bioluminescence imaging, a Semrock light filter FF01-460/60 was used to capture 
NanoLuc emission. Images were processed using Fiji (version 1.51r). 
  
Next generation sequencing 
 Genomic DNA was isolated 72 hr post-transfection using the Quick-DNA 
Miniprep Plus kit (Zymo Research) and eluted into 25 μl 10 mM Tris-HCl, pH 8. A 
150-250 bp region encompassing each targeted locus was PCR amplified from 
~40 ng genomic DNA with ends containing partial Illumina adapter sequences 
using CloneAmp HiFi PCR (Takara). Reaction conditions were as follows: 98 °C 
for 1 min, then 30 cycles of 98 °C for 10 sec, 55 °C for 10 sec, and 72 °C for 5 sec. 
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1 μl of each unpurified amplicon was then carried to a second PCR reaction using 
KAPA HiFi Library Amp (Roche Sequencing). NEBNext Multiplex Oligos (New 
England Biolabs) were used to add single indexes to the amplicons. Reaction 
conditions were as follows: 10 cycles of 98 °C for 20 sec, 61 °C for 15 sec, and 72 
°C for 15 sec. 2 μl of each common amplicon were pooled and gel purified from a 
1.5% agarose gel (Nucleospin clean-up, Takara Bio), eluting in 35 μl 10 mM Tris-
HCl, pH 8. Common amplicon libraries were quantified with qPCR using NEBNext 
Library Quant kit (New England Biolabs) and pooled to equal concentrations. 
Sequencing was performed with an Illumina MiSeq with 2 x 150 bp paired-end 
reads (Genewiz). Sequencing reads were demultiplexed and analyzed using 
CRISPResso2 in batch mode155. 
  
GFP to BFP editing 
 HEK-293 cells stably expressing GFP were plated at 200,000 cells per well 
24 hr prior to transfection. 250 ng of prime editor, 100 ng of pegRNA, and 50 ng of 
mCherry plasmid was then transfected using Lipofectamine 3000 (Invitrogen). For 
PE3 experiments, 100 ng of gRNA was also added. Cells were then incubated for 
72 hr and analyzed using flow cytometry, gating for mCherry and BFP positive. 
  
PIGA editing 
 PIGA- cell lines (HCT116 clone #2D2 or RPE1 clone #1A10) were co-
transfected with 500 ng pegRNA plasmid and 1.5 µg DNA of full-length SaPE or 
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750 µg each of split SaPE plasmids. 1x106 cells were electroporated using the 
Neon Transfection System (1530 V, 10 ms, 3 pulses, 10 µL tips). Transfected cells 
were transferred to prewarmed media in 10 cm plates and incubated for 72 hours 
prior to collection for downstream analysis. 
 
Western blot 
 Lysates were collected 72 hr post-transfection from HEK-293T cells in 24-
well plates using RIPA buffer containing protease inhibitors. One third volume of 
each lysate was electrophoresed on a 4-20% SDS-PAGE gel and transferred to a 
nitrocellulose blot. The blot was blocked in 5% milk in TBS-T then incubated 
overnight at 4 °C with 1:1000 dilutions of primary antibody. Primary antibodies 
used were mouse anti-FLAG M2 (F1804; Sigma) or the loading control mouse anti-
β-tubulin (T8328; Thermo Fisher). Blots were washed and then incubated for 1 hr 
with 1:10000 goat anti-mouse IgG-HRP (62-6520; Invitrogen). Blots were imaged 




 All viral vectors used in this study were generated by the University of 
Minnesota Viral Vector and Cloning Core (Minneapolis, MN). Briefly, AAV293 cells 
at 60% confluence were transfected with 600 μg of DNA (viral shuttle vector 
encoding the payload, helper plasmid, rep/cap plasmids at 1:1:1 ratio) using 
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polyethylenimine. 24 hr after transfection, the media was changed, and cells were 
checked for fluorescent protein expression (when applicable) to confirm 
transfection. 72 hr after transfection, cells were detached and pelleted. Viral 
particles were released from producer cells by repeated freeze/thaw cycles in the 
presence of Benzonase (100 units). Crude lysates were cleared by centrifugation 
and further purified using sucrose gradients. Viral particles in the supernatant were 
titered using qPCR with ITR-specific primers. Kanamycin-specific primers were 
used to confirm the absence of plasmid DNA after Benzonase treatment. 
  
AAV transduction 
 HEK-293T cells were plated 24 hr prior to transduction at 50,000 cells per 
well. Cells were washed with 1x DMEM (no FBS) and AAV diluted in DMEM was 
added gently on top. Experiments were performed at ~1 × 106 g.c.(genome 
copies)/cell per virus. 1 hr after virus addition, 1 ml of D10 was added on top in 
each well. 24 hr post-transduction, media was aspirated and 500 µl fresh D10 was 




Development of an S. aureus prime editor  
As SaCas9 and SpCas9 share similar domain architecture, we reasoned that 
a nickase SaCas9 could serve as a sufficient nicking nuclease to be combined with 
the prime editing methodology. We generated the analogous HNH domain 
mutation in SaCas9 (N580A) as in SpCas9 (H840A) and tethered a reverse 
transcriptase to create an S. aureus prime editor, SaPE (Figure 3.1a). The 
previously engineered version of Moloney murine leukemia virus reverse 
transcriptase (eMMLV-RT) was utilized147. We then sought to create a split version 
of SaPE capable of fitting into two AAV genomes. Numerous methods have been 
applied to efficiently recombine split portions of Cas963,156. We utilized a split intein-
mediated approach wherein the split Npu trans-splicing intein from Nostoc 
punctiforme was appended onto the N- and C-termini of split SaPE157 (Figure 
3.1a). We trialed three different split locations in SaCas9, all of which have been 
previously reported64,152. Two of the split locations, E739/S740 (version 1) and 
K534/C535 (version 3), showed reasonable intein splicing in cells (Figure 3.1b). 
To more quickly test editing conditions, we created a stably integrated 
fluorescent reporter cell containing a point mutation in GFP(L202S) that ablates 
GFP fluorescence linked to mKate2 via a 2A self-cleaving peptide158 (Figure 3.1c). 
The restoration of GFP fluorescence through a +6 G to A transition point mutation 
can readily be detected using microscopy or flow cytometry (Figure 3.1d). We first 
tested full-length and split versions of SaPE alongside a variant with the RT 
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tethered to the amino terminus of nSaCas9 (PESa). In comparison with SpPE, 
SaPE had an 8-fold reduction in editing efficiency (Figure 3.1e). While SaPE 
editing efficiencies were low at around 0.5%, all split versions had comparable 
levels to full-length SaPE. These low editing frequencies with SaPE, as elaborated 
on in the Discussion, are a trend that generally holds true at most loci. Decreases 
in editing efficiency might be attributed to, among other factors, shorter residency 
time of SaPE on the DNA as opposed to SpPE159. Nonetheless, detectable levels 
of prime editing driven by SaPE are observed. 
Prime editing necessitates optimization of the pegRNA 3’ extension design 
as both the RT template and primer binding site (PBS) lengths appear to be edit 
type and locus dependent147,160,161. At the GFP(L202S) locus, we interestingly 
observed little difference in editing frequencies when sampling altered 3’ extension 
designs (Figure 3.1f). Variation did exist among the three split versions, and in 
these sets of experiments, split SaPE had noticeable decreased editing 
frequencies compared to full-length. Combined with the intein splicing and editing 
profiles, we carried forward predominantly with version 3 of sSaPE (K534/C535). 
In another fluorescent assay targeting a different locus in GFP, we once again 
compared SpPE to SaPE. A two amino acid change in GFP (T65S-Y66H) converts 
the fluorescence to BFP162. When prime editing reagents were transfected in HEK-
293 cells stably expressing GFP, we observed a similar frequency of editing 
between full-length and split SaPE (1.85% versus 2.45%) (Figure 3.1g). This was 
again lower than SpPE (3.6%) but to a lesser degree than GFP(L202S) where 
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SpPE editing was almost an order of magnitude higher. Conversion to BFP was 
also seen in HCT-116 cells to a similar degree as in HEK-293 cells 
(Supplementary Figure 3.1). Interestingly, PAM sequence constraints required 
this edit to be upstream from the nick site (-1 site) in addition to a +2 point mutation. 
The ability of prime editor to make modifications upstream of the predicted nick 
site, 3 bp away from PAM, lends itself to past research suggesting Cas9 also can 
cleave 4 bp upstream163. While this effect might be locus dependent, we observed 
appreciable editing and potentially a broadened capability of prime editor. 
  
Optimization of split SaPE 
To try increasing editing frequencies at the GFP(L202S) locus with SaPE, we 
next sought to optimize experimental parameters and platform design. We 
performed a titration of plasmid DNA concentration using lipofection while the 
molar ratio of PE:pegRNA was held constant. Due to the PE vectors being 
approximately three times the size of the pegRNA plasmids in bp, this resulted in 
a 3:1 ng of DNA concentration ratio. The maximal editing of ~0.6% was seen at 
surprisingly the lowest concentration of DNA. (Supplementary Figure 3.2). In the 
case of sSaPEv3, higher DNA concentrations resulted in roughly a 33% decrease 
in editing efficiency. Cytotoxicity associated with large plasmids combined with 
excess amounts of DNA could be a cause of this trend164. 
Next, two previously described linkers were installed in place of the built-in 
one between nSaCas9 and RT to try enhancing editing rates: XTEN165, found in 
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base editors, and (H4)2, a rigid alpha helical linker of the sequence (A(EAAAK)4A)2 
166. While the XTEN linker performed as well as the original SaPE linker, the 
replacement with the (H4)2 linker ablated prime editing (Supplementary Figure 
3.2). This difference highlights the crucial, but often ignored, impact of spatial 
orientation of components in fusion proteins. Further exploration of linkers and 
different permissible fusion locations of RT on nCas9 could be carried out to try 
optimizing this key parameter. 
Another approach we utilized to try boosting editing rates was to employ the 
3rd generation prime editor system, termed PE3147. PE3 uses a second gRNA that 
nicks the non-prime edited strand to encourage DNA repair machinery to 
preferentially repair the nicked strand once the desired edit has been incorporated. 
The hypothesis is to push the equilibrium of flap resolution and DNA repair towards 
the desired outcome, a method successfully used in base editors144. Due to the 
limited number of SaCas9 PAM motifs in the vicinity of the targeted location in 
GFP(L202S), we could only assess two PE3 gRNAs in combination with SaPE. 
Use of either gRNA, which nick at -70 or -51 bp from the +1 site, resulted in lower 
editing efficiencies for sSaPEv3 (Supplementary Figure 3.2). For sSaPEv1, the -
51 gRNA caused a dramatic tripling in editing efficiency (0.20% to 0.67%) while 
the -70 gRNA had little effect. PE3 has been shown to be moderately successful 
at improving prime editing at other loci with SpPE147,167. We chose, however, not 
to generally pursue the PE3 approach at other loci due to the limited amount of 
neighboring PAM sequences available. Taken together, our efforts to optimize 
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SaPE did little to improve editing rates from the outset in the context of the 
GFP(L202S) locus. 
  
Broad assessment of SaPE 
         We next wanted to assess SaPE and sSaPEv3 across a wide range of loci 
and editing types while also changing the lengths of the 3’ extension components 
of pegRNA. Using next-generation sequencing, we found SaPE capable of making 
wide-ranging precise changes to target loci (Figure 3.2). In sampling different RT 
template and PBS lengths at the EMX1 locus in a +6 G to T transversion point 
mutation, we found variable editing rates between 0.3% and 2.1% for full-length 
SaPE (Figure 3.2a). For split SaPE, less variability existed, but editing rates were 
limited to between 0.3% and 0.5%. Split SaPE tended to have a decreased editing 
frequency across all loci tested, a trend that is not uncommon with split Cas962,63 
but is in contrast to what was observed with split base editor64. At both the FANCF 
and DNMT3B loci, editing rates peaked around 0.4% for a range of point 
mutations, insertions, and deletions (Figure 3.2b and c). Point mutations, 
however, tended to yield higher editing efficiencies than insertion or deletions. In 
varying the RT template length at RUNX1, the longer length (15 nt) yielded 
improved editing over the shorter RT template (10 nt), regardless of the location of 
the edit from the nick site (Figure 3.2d). In the case of the further +7 G to A 
mutation, a 10 nt RT template resulted in nearly undetectable levels of editing. 
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The highest prime editing frequencies were seen at the HEK3 locus, where a 
+3 C to A transversion was formed in 9.2% of full-length SaPE transfected loci and 
nearly 5% in the sSaPEv3 condition (Figure 3.2e). At the same target site, a series 
of 5mer deletions were encoded in the pegRNA, ranging from 5 to 25 bp in length. 
Editing frequencies were 1.9% and 1% for SaPE and sSaPEv3, respectively, for a 
5 bp deletion (Figure 3.2f). These rates decreased as the deletion length 
increased. 25 bp deletions were still detected, albeit at a lower frequency than 
other deletion lengths. 
We repeated some of the above experiments in U2-OS cells to explore cell 
type dependency. Overall, no trend emerged in regard to predicting optimal editing 
frequency at a given target locus, edit type, and pegRNA design. Editing 
efficiencies were in the single digits across all loci assayed, although the HEK3 
locus offers promise moving forward. 
 
Altering the dimerization domain 
Following extensive characterization of the editing frequencies, we aimed to 
better understand the split protein recombination requirements. To visualize 
reassociation of split SaPE, we replaced the Npu split intein with split NanoLuc 
(Figure 3.3a). Split NanoLuc (sNanoLuc, sNL), with a KD of 700 pM, is comprised 
of an 18 kDa N-terminal fragment, LgBiT, and a 13 amino acid C-terminal portion, 
HiBiT168. When co-transfecting the two halves of sSaPE-sNanoLuc, we saw 
extensive nuclear reconstitution of NanoLuc in a vast majority of cells using 
 85 
bioluminescence microscopy (Figure 3.3b). Similar editing rates to sSaPEv3 were 
also seen, indicating that sNanoLuc is sufficient to act as a dimerization domain in 
the context of SaPE (Figure 3.3c). The lack of requiring covalent association of 
the two halves of SaPE was further evaluated by utilizing a catalytically inactive 
version of the Npu intein (C1A). In these constructs, the two intein components 
can associate but not self-splice. No covalent full-length SaPE is formed, yet 
editing rates are on par with the catalytically active intein version (Figure 3.3c and 
d). This data further validated that covalent association of the two halves of split 
SaPE is not required to reconstitute active SaPE. The use of sNanoLuc also offers 
a convenient system in which visual confirmation of recombined SaPE is possible, 
an approach which can be utilized with AAV delivery. 
  
Packaging and delivery of SaPE in AAV 
Next, we cloned the N- and C-terminal portions of sSaPE versions 1 and 3 
into AAV genomes containing flanking ITRs. For N-terminal sSaPE, two 
orientations of the U6 promoter-pegRNA cassette were tested, either in tandem or 
in reverse alignment to the protein expression cassette (Figure 3.4a). The C-
sSaPEv3 AAV genome is 4.8 kb in length while the N-terminal genomes are 
approximately 3.5 kb. Before packaging into virus, AAV plasmids were co-
transfected targeting GFP(L202S) to ensure editing still occurred in the different 
context. Indeed, editing rates were in line with previous plasmid designs, even with 
a co-transfection as opposed to a triple transfection (Figure 3.4b). Next, AAV-DJ 
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was packaged and titered using qPCR, yielding ~2x1010 viral genome copies 
(g.c.)/μl. A control transduction with tdTomato as the encoded genome exhibited 
robust delivery and fluorescent protein expression in HEK-293T cells 
(Supplementary Figure 3.4), ensuring proper production and purification of the 
virus. We co-transduced sSaPE AAVs in GFP(L202S) HEK-293T cells and first 
assessed protein recombination. At both three and five days post-transduction, 
full-length recombined protein was evident via western blot (Figure 3.4c). 
Assessing GFP fluorescence restoration in GFP(L202S), we see a concentration 
dependent increase in editing (Figure 3.4d). While the GFP restoration frequency 
is low, co-delivery of sSaPEv3-sNanoLuc AAVs in these cells also showed a low 
number of cells expressing recombined protein, potentially due to a low co-
transduction efficiency (Supplementary Figure 3.4). However, co-transduction in 
U2-OS cells resulted in an order of magnitude increase in delivery and 
recombination efficiency as visualized by bioluminescence microscopy (Figure 
3.4e). Taken together, we have begun the proof of concept work necessary to 





We have demonstrated that an S. aureus prime editor presents a platform 
upon which in vivo prime editing can occur. While the editing rates we achieved in 
vitro were overall low (typically 0.5 to 1%) and not likely to be effective for many 
diseases, this approach offers a starting point to further refine and improve. It is 
important to note that comparably poor prime editing rates, albeit in plants and 
protoplasts, were seen in other published reports with SpPE160,167. Multiple 
engineering approaches can be undertaken to increase the efficiency of the 
system. To enhance activity with SaCas9, directed evolution of MMLV-RT could 
be employed to increase activity on pegRNA:R-loop DNA in a method akin to a 
recently evolved adenosine base editor169. A circularly permuted version of 
SaCas9 to facilitate the optimal RT fusion location could also be created, similar 
to what was also performed with base editors170, to increase access to the R-loop 
DNA. Another reason SaCas9 might have diminished prime editing rates could be 
attributed to a decreased residency time on the DNA target159. Chemically or 
genetically disrupting factors involved in removing Cas9 from genomic DNA has 
been successful at increasing other Cas9-fused effector functions. In one such 
study, genetic knockdown of the histone chaperone FACT increased Cas9 
residence on DNA and led to improved epigenetic marking and CRISPRi171. It is 
also interesting to note that using the sSaPE-sNanoLuc platform, we see that the 
construct is being expressed in a majority of the cells (Figure 3.3b). A recent study 
examining pegRNA design principles does provide insight into optimal pegRNA 
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design, although how well it translates to SaPE remains to be seen172. Further 
investigation, aided by the preceding suggestions, is warranted into studying the 
underlying reasons behind the disconnect between expression and prime editing. 
A downside of SaCas9 is the more limited reach in genomic space with a 
longer PAM sequence of NNGRRT. This limitation is especially relevant as 
mutations further away from the +1 site tended to have lower editing rates. 
However, iterations such as SaCas9 (KKH) have lessened the PAM specificity 
(PAM = NNNRRT)173. Such codon changes could feasibly be incorporated to SaPE 
to expand the targeting range. Additionally, SaPE is a less ideal system for a PE3 
type system, wherein a second gRNA nicks the non-editing strand to encourage 
the desired editing outcome, due to the stricter PAM specificity. A less stringent 
PAM could aid in a broader exploration of PE3 with SaPE. 
Once we are able to demonstrate in vitro AAV delivery of sSaPE, the next 
phase will be to test in vivo. The ultimate goal is to perform delivery using targeted 
delivery approaches such as HUH-AAV78. This could have the advantage of 
decreasing the necessary administered dose, potentially limiting immunogenicity, 
and alleviating non-target cell editing concerns. In conclusion, this work provides 
a baseline platform for prime editor to be delivered in vivo. Through making an S. 
aureus prime editor and combining with trans splicing intein technology, we are 
able to package prime editor into dual AAVs for delivery. The anticipated 
engineering advances that will be made with prime editing components, such as 
increased DNA residency time or enhanced RTs, can readily be incorporated into 
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this platform to increase editing efficiencies and move prime editing towards the 
clinic. 
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Enabling precise genome modifications using a split S. aureus prime editor. 
(a) Schematic of both full-length S. aureus prime editor (SaPE) and split SaPE 
(sSaPE). (b) Western blot of plasmid-based expression of three different versions 
of sSaPE. Successful trans intein splicing is denoted by the arrow next to the 
higher molecular weight band. (c) Model system for analyzing editing by SaPE 
using a GFP(L202S) stable reporter line to restore GFP fluorescence. A single 
point mutation (G to A) that lies within SaPE’s PAM is required. The antisense DNA 
sequence is shown. (d) Representative fluorescence microscopy images of 
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unedited (-PE) and edited (+PE) HEK-293T stably expressing the GFP(L202S)-
2A-mKate2 reporter. Scale bar = 20 µm. (e) Quantitation of prime editing in HEK-
293T cells using flow cytometry. S. pyogenes prime editor (SpPE) is compared to 
full-length SaPE, N-terminally fused RT-nSaCas9 (PESa), and three versions (v1-
v3) of sSaPE. No pegRNA corresponds to transfection of SaPE only. Data are 
representative of multiple independent experiments. (f) Targeting of GFP(L202S) 
reversion with pegRNAs of differing 3’ extension lengths (PBS = primer binding 
site). (g) GFP to BFP editing in HEK-293 cells stably expressing wildtype GFP. 






SaPE is capable of diverse edit types across various genomic loci. (a-f) Next-
generation sequencing readouts of targeting of SaPE and sSaPEv3 to indicated 
loci (a) EMX1, (b) FANCF, (c) DNMT3B, (d) RUNX1, and (e,f) HEK3 with differing 
edit types and pegRNA architectures. (f) contains the same 5mer deletion series 







Split NanoLuc substitutes as an effective dimerization domain and 
visualization tool. (a) Diagram of sSaPE-split NanoLuc (sNL) (not to scale). (b) 
Composite image of stable GFP(L202S)-2A-mKate2 HEK-293T cells transfected 
with sSaPE-sNL. Colors are as follows: red = mKate2; blue = NanoLuc; green = 
GFP. Scale bar = 120 µm. (c) Prime editing rates at GFP(L202S) locus in HEK-
293T cells. (d) Western blot of co-transfection of indicated versions of split SaPE. 
Only the N-terminal fragment is FLAG labeled. The top band corresponds to 






Packaging of split SaPE into AAV. (a) Scheme of different layouts of sSaPE in 
AAV genome with indicated sizes of expression cassettes. (b) Plasmid-based 
prime editing of SaPE encoded in AAV plasmids. Version 3.2-sNL corresponds to 
sNanoLuc replacing Npu intein. (c) Western blot of HEK-293T cells transduced 
with the indicated virus(es) for 3 or 5 days. Only the N-terminal fragment is FLAG 
labeled. (d) Co-transduction of AAVs expressing sSaPEv3 at the indicated 
multiplicity of infections (genome copies / cell) targeting GFP(L202S). (e) 
Bioluminescence microscopy images of co-transduced AAV-sSaPEv3-sNanoLuc 
in U2-OS cells after 4 days. 
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Supplemental Figure 3.1 
 
 
Conversion of GFP to BFP. (a) Editing scheme of converting GFP to BFP through two 
point mutations. (b) Percentage of GFP converted to BFP in HEK-293 and HCT-116 cells 
electroporated with the indicated prime editors as analyzed by flow cytometry. Two 
different pegRNAs were trialed for SaPE. 
  
 96 
Supplemental Figure 3.2 
 
 
Optimization of SaPE using GFP(L202S) reporter system. (a) Titration of both full-
length and split SaPE. DNA concentrations on the x-axis correspond to prime 
editor/pegRNA amounts. (b) Comparison of various versions of SaPE, including altering 
the linker between nSaCas9 and RT. (c) Combining SaPE with a gRNA nicking on the 
non-edited strand at the indicated position to drive incorporation of the desired edit. 
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Supplemental Figure 3.3 
 
Prime editing in U2-OS cells. (a) Next generation sequencing results of prime editing at 
the RUNX1 locus of a +1 A to T mutation in both HEK-293T (left) and U2-OS cells (right). 
Different RT template lengths in the pegRNA are used while the PBS is held constant at 
8 bp in length. (b) Prime editing comparison at the HEK3 locus in different cell types. 
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Supplemental Figure 3.4 
 
AAV-mediated delivery of tdTomato and SaPE. (a) AAVs containing TdTomato as the 
cargo were transduced in 293T-GFP(L202S)-2A-mKate2 reporter cell line. 48 hr post-
transduction, cells were analyzed using flow cytometry and compared to non-transduced 
cells. (b) Microscopic images of co-transduction of sSaPEv3-sNanoLuc encoded in AAVs 
in HEK-293T cells. Scale bar is 50 µm. MOI = Multiplicity of Infection. 
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Spacer sequence (5’ to 3’) Modification RT template PBS 
EMX1 GGCCTCCCCAAAGCCTGGCCA +6 G to T ctggccactAcctgg ccaggctttgggg 
EMX1 GGCCTCCCCAAAGCCTGGCCA +6 G to T cactAcctgg ccaggctttg 
EMX1 GGCCTCCCCAAAGCCTGGCCA +6 G to T ctggccactAcctgg ccaggctttg 
EMX1 GGCCTCCCCAAAGCCTGGCCA +6 G to T cactAcctgg ccaggctt 
L202S-
GFP 
TTGCTCAGGGCCGACTGGGTAC +6 G to A ACCACTAttTaAGtA CCCAGTCgGCCCT 
L202S-
GFP 
TTGCTCAGGGCCGACTGGGTAC +6 G to A ACCACTAttTaAGtA CCCAGTCg 
L202S-
GFP 
TTGCTCAGGGCCGACTGGGTAC +6 G to A ttTaAGtA CCCAGTCgGCCCT 
L202S-
GFP 
TTGCTCAGGGCCGACTGGGTAC +6 G to A ttTaAGtA CCCAGTCg 
RUNX1 GTACTCACCTCTCATGAAGCACT +6 G to C CTTCGTACCgACAGT GCTTCATG 
RUNX1 GTACTCACCTCTCATGAAGCACT +6 G to C TACCgACAGT GCTTCATG 
RUNX1 GTACTCACCTCTCATGAAGCACT +7 G to A CTTCGTACtCACAGT GCTTCATG 
RUNX1 GTACTCACCTCTCATGAAGCACT +7 G to A TACtCACAGT GCTTCATG 
RUNX1 GTACTCACCTCTCATGAAGCACT +1 A to T CTTCGTACCCACAGa GCTTCATG 
RUNX1 GTACTCACCTCTCATGAAGCACT +1 A to T TACCCACAGa GCTTCATG 
FANCF gtagggccttcgcgcacctca +1 A to C gaagggattccatgC ggtgcgcg 
FANCF gtagggccttcgcgcacctca +1 A to C gattccatgC ggtgcgcg 
FANCF gtagggccttcgcgcacctca +2 G to C gaagggattccatCa ggtgcgcg 
FANCF gtagggccttcgcgcacctca +2 G to C gattccatCa ggtgcgcg 
FANCF gtagggccttcgcgcacctca +3 T to G gaagggattccaGga ggtgcgcg 
FANCF gtagggccttcgcgcacctca +3 T to G gattccaGga ggtgcgcg 
GFP/BFP GAAGCACTGCACGCCGTAGGT +2 G to C / -
1 C to T 
GACCACCCTGAgCc ACGGCGTGCAGT 
GFP/BFP GAAGCACTGCACGCCGTAGGT +2 G to C / -
1 C to T 
ACCCTGAgCc ACGGCGTG 
HEK3 tctgcttctccagccctggc +3 C to A ttgacccagTcc agggctggag 
HEK3 tctgcttctccagccctggc +1 5mer 
deletion 
ggattgaccc agggctggag 
HEK3 tctgcttctccagccctggc +1 10mer 
deletion 
cccaaggatt agggctggag 
HEK3 tctgcttctccagccctggc +1 15mer 
deletion 
tgggccccaa agggctggag 
HEK3 tctgcttctccagccctggc +1 20mer 
deletion 
cagtctgggc agggctggag 
HEK3 tctgcttctccagccctggc +1 25mer 
deletion 
gtgctcagtc agggctggag 
FANCF gatgttccaatcagtacgca +6 G to C cggcgactGtctgc gtactgattgga 
FANCF gatgttccaatcagtacgca +1 ATG_ins cggcgactctctgcCAT gtactgattgga 
FANCF gatgttccaatcagtacgca +3 TT_ins cggcgactctcAAtgc gtactgattgga 
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FANCF gatgttccaatcagtacgca +1 tgc del agacggcgactctc gtactgattgga 
FANCF gatgttccaatcagtacgca +8 G to T cggcgaAtctctgc gtactgattgga 
DNMT3B ggtggcactgcggctggaggt +6 G to C ctttaaccGccacc tccagccgcagt 
DNMT3B ggtggcactgcggctggaggt +2 AA ins ttaacccccacTTc tccagccgcagt 
DNMT3B ggtggcactgcggctggaggt +1 ggt del tttaaccccc tccagccgcagt 
DNMT3B ggtggcactgcggctggaggt +3 G5_del ctccgctttaaacc tccagccgcagt 
 
For spacer sequences that don’t begin with a G nucleotide, one was added to aid in U6-
driven expression of the pegRNA. Modifications are listed relative to the +1 nick site 3 
nucleotides upstream from the PAM on the sense DNA strand.  
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Supplemental Table 3.2 
 
Primers used for genomic DNA amplification. 
Name Sequence (5’ to 3’) 
SpEMX1_F ACACTCTTTCCCTACACGACGCTCTTCCGATCT CAGCTCAGCCTGAGTGTTGA 
SpEMX1_R GACTGGAGTTCAGACGTGTGCTCTTCCGATCT CTCGTGGGTTTGTGGTTGC 
L202S_F ACACTCTTTCCCTACACGACGCTCTTCCGATCT TTCAAGATCCGCCACAACAT 
L202S_R GACTGGAGTTCAGACGTGTGCTCTTCCGATCT GTATAGTTCATCCATGCCGAG 
SaEMX1_F ACACTCTTTCCCTACACGACGCTCTTCCGATCT gcaaccacaaacccacgag 
SaEMX1_R GACTGGAGTTCAGACGTGTGCTCTTCCGATCT agacacggagagcagctg 
RUNX1_F ACACTCTTTCCCTACACGACGCTCTTCCGATCT GAGGGTGCATTTTCAGGAGG 
RUNX1_R GACTGGAGTTCAGACGTGTGCTCTTCCGATCT CAAGCTGCCATTTCATTACAGG 
FANCF_F ACACTCTTTCCCTACACGACGCTCTTCCGATCT ccagagtcaaggaacacgga 
FANCF_R GACTGGAGTTCAGACGTGTGCTCTTCCGATCT acgtaggtagtgcttgagacc 
DNMT3B_F ACACTCTTTCCCTACACGACGCTCTTCCGATCT gaacccaggtagccagagac 
DNMT3B_R GACTGGAGTTCAGACGTGTGCTCTTCCGATCT tcctttcaacccgaacggag 
HEK3_F ACACTCTTTCCCTACACGACGCTCTTCCGATCT ggaaacgcccatgcaattag 




Supplemental Table 3.3 
SaPE Protein sequences. 














































































































































Supplemental Note 3.1 
Cloning SaPE pegRNAs using golden gate assembly. 
 
The pegRNAs were cloned using a protocol adapted from the Liu lab (Anzalone, 
et al., 2019). These modifications were made to incorporate the S. aureus gRNA 
scaffold sequence and to add some streamlined features in regard to vector 
digestion and golden gate assembly cycling conditions. 
 
Step 0: Design of oligonucleotides 
Protospacer oligonucleotides 
Forward: CACC ...(spacer sequence).... GTTTT 
Reverse: TACTAAAAC …(reverse complement spacer)... 
Note: Add a G prior to spacer sequence if it doesn’t begin with a G (and 
corresponding C on reverse oligonucleotide). 
 
pegRNA 3’ extension oligonucleotides 
Forward: GAGA …(RT template + PBS)... 
Reverse: AAAA …(reverse complement)... 
 







Step 1: Anneal oligonucleotides 
In IDT annealing buffer (30 mM HEPES pH 7.5, 100 mM KAc), add equimolar 
amounts of forward and reverse oligonucleotides to 1 μM. Heat to 95 °C for 3 
minutes then cool to room temperature at 0.1°C/s. Unused annealed 
oligonucleotide can be stored at -20°C. 
 
Step 2: Golden gate assembly reaction 
Undigested pU6-pegRNA-RFP acceptor (Addgene #132777)              1 μL @ 250 
ng/μL 
Annealed protospacer oligonucleotides                                   1 μL @ 1 
μM 
Annealed pegRNA 3’-extension oligonucleotides                1 μL @ 1 
μM 
Annealed phosphorylated sgRNA scaffold oligonucleotides               1 μL @ 1 
μM 
BsaI-HFv2 (NEB)                                                                                    0.25 μL 
T4 DNA ligase (NEB)                                                                              0.50 μL 
10x T4 DNA ligase buffer (NEB)                                                                  1 μL 
 106 
H2O                                                                                                          4.25 μL 
Total reaction volume                                                                              10 μL 
  
 
Perform the following program in a thermocycler: 
Cycle 10x: 
5 min at 37 °C 
10 min at 16 °C 
Following cycles, incubate at 5 min at 55°C followed by 5 min at 85°C then hold 
at 12°C 
  
Step 3: Transformation 
Transform 1 μL of the assembly reaction into competent E. coli cells of your 
choosing. Plate on LB Agar, incubate overnight at 37 °C, and inoculate non-red 
colonies for DNA miniprep. 
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Supplemental Note 3.2 
Flow cytometry gating strategy and representative plots. 
1. Gating on live cells SSC-A vs FSC-A 
2. Gating on single cells (omitting aggregates) FSC-H vs FSC-W 








In vivo gene delivery to prostate tumors via an anti-fibroblast activation 
protein antibody-AAV composite  
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Prostate cancer is a heterogeneous disease usually diagnosed in late stages, 
making treatment challenging and frequently ineffective174. There is a need for new 
treatment and diagnostic methods. Fibroblast activation protein alpha (FAP) is a 
surface marker expressed on stromal cancer-associated fibroblasts that has 
recently been shown to be an effective marker of prostate tumors175. Our lab has 
described a technology to redirect adeno-associated virus (AAV) infection to be 
dependent upon an antibody-antigen interaction78. In this study, we aimed to 
create a cancer gene therapy vector by conjugating an anti-FAP antibody to the 
capsid of this modified AAV. We characterized formation of this composite using 
electron microscopy. Initially, we delivered a near-infrared fluorescent protein to 
mice with FAP+ xenografted tumors. Future studies will deliver therapeutic genes 






Prostate cancer is a leading cause of cancer death in men, responsible for 
375,304 deaths in 2020 alone 176. Treatment options are typically limited to surgical 
removal of the prostate and/or castration, hormone therapy, and radiotherapy, all 
of which have major side effects 174. Patients with aggressive metastatic prostate 
cancer frequently stop responding to standard of care treatments and are left with 
few options 177. There is a need for new therapeutics capable of treating 
heterogeneous, late-stage prostate tumors. 
Recently, an antibody that binds murine fibroblast activation protein alpha 
(FAP), a protein expressed in stromal fibroblasts in prostate and other cancers has 
been characterized 178. The stroma can account for up to 90% of tumor mass, 
making it an attractive target for chemotherapy 179. FAP expression is largely 
restricted to stromal cancer associated fibroblasts (CAFs), meaning that any 
therapeutic delivered to FAP-expressing cells would minimally effect healthy cells 
180. Past studies have demonstrated that killing FAP+ stromal fibroblasts inhibits 
growth of xenografted tumors, further supporting the idea that targeting the CAFs 
is an effective treatment180. Additionally, in in metastatic castration-resistant 
prostate cancer, FAP has been shown to be a reliable tumor marker, providing an 
improved therapeutic and diagnostic target 175.  
Targeted chemotherapeutics are key to minimizing side-effects and off-target 
cell death. One way to achieve targeted delivery of therapeutics is with antibody-
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drug conjugates. One antibody-drug conjugate (ADC) that has been used is 
composed of an anti-tumor endothelial marker 8 (TEM8) antibody conjugated to 
monomethyl auristatin E (MMAE), a drug commonly used in ADCs 181,182. The ADC 
effectively homed to TEM8, which is expressed in CAFs, but the drug has limited 
use because MMAE response varies greatly between tumor cell lines 182. With any 
chemotherapeutic, it is likely that the carcinoma will eventually grow resistant to 
treatment 183. While there may be alternate routes of treatment, the limited 
plasticity of small molecules for ADCs makes them a cumbersome route of action. 
In contrast to small molecule chemotherapeutics, cancer gene therapy is 
highly plastic. Gene therapy for prostate cancer has gained popularity in recent 
years, with several therapeutics progressing to phase I and II clinical trials 184. The 
genes delivered in these strategies broadly either recruit the immune system or 
attempt to induce cell death. Many different therapeutic gene products (i.e. siRNA, 
RNAi, proteins, miRNA, etc.) and their mechanisms of action have been 
characterized, 185. Additionally, once a delivery mechanism has been selected, 
modifying treatment from one gene to another is relatively easy and quick. 
Additionally, even small vectors typically have space to deliver more than one gene 
product, making them an ideal platform for simultaneous delivery of a therapeutic 
and diagnostic. One gene delivery vector that is gaining popularity for cancer gene 
therapy is adeno-associated virus (AAV) 71,72. However, natural serotypes of AAV 
do not specifically target cancerous cells, resulting in delivery of therapeutic genes 
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to healthy tissue. The main challenge precluding cancer gene therapy from 
widespread adoption at this point is the lack of a safe, targeted delivery vector 74.  
Recently, our lab has characterized a system of covalently conjugating AAV 
to an antibody to facilitate antibody-mediated infection 78. The vector is modified 
via engineering one of the AAV capsid proteins to contain a small single-stranded 
DNA (ssDNA) binding domain called an HUH tag. In this context, the HUH tag 
forms a covalent bond with its matched sequence of ssDNA 120. An antibody can 
be attached to this ssDNA sequence using commercially-available copper-free 
click chemistry. By reacting this ssDNA-antibody with the HUH-modified AAV 
capsid, a fully covalent antibody-AAV composite is formed. Additionally, the native 
tropism of the virus is removed by mutating regions of the capsid responsible for 
heparin sulfate and beta-integrin binding 34. Resultantly, this modified virus is only 
able to bind and infect cells via the antibody-antigen interaction.  
To further characterized this antibody-AAV composite, we imaged capsids 
using transmission electron microscopy. It is known that the HUH tag used in the 
capsid is not 100% efficient, and that rates of incorporation of modified viral 
proteins can vary120. Viral titer is calculated by number of genome-containing 
capsids, whether they are conjugated to an antibody or not. Given this information, 
we wanted to know approximately what percentage of genome-containing capsids 
were conjugated to an antibody.  This measure should provide a more accurate 
“effective titer” of the number of viruses capable of infecting cells via the FAP-
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antibody interaction, which would be a truer point of comparison of infectivity 
relative to unmodified AAV-DJ.   
We aimed to selectively deliver genes to CAFs by conjugating the anti-FAP 
antibody to this modified AAV capsid. Initially, we delivered a fluorescent protein 
(miRFP670) to confirm specific delivery of the gene to the tumor. miRFP670 is a 
near-infrared fluorescent protein that can be imaged in vivo186. Data from two 
experiments were collected with two or three biological replicates for each 
experimental group. We also collected electron microscopy data characterizing the 
conjugated virus to gain a better idea of conjugation efficiency. Future work will 
investigate whether tumor growth can be inhibited by delivering therapeutic genes 
alongside imaging components. 
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Methods & Materials 
  
Antibody Production and Conjugation 
Anti-FAP antibody was produced as previously described 178. Briefly, both 
domains were cloned into IgG expression vectors and cotransfected into HEK293 
cells. Antibody was harvested from serum and purified using a HiTrap Protein A 
HP column (GE Healthcare). Human IgG isotype control was purchased from 
ThermoFisher. 3’ amino-labeled mMobA ori ssDNA sequence was ordered from 
Integrated DNA Technologies (Coralville, IA). Each antibody and ssDNA were 
conjugated using an abcam Oligonucleotide Conjugation Kit at an estimated ratio 
of 3:1 ssDNA:antibody. Free ssDNA was removed and conjugate formation was 
verified via SDS-PAGE.  
 
Virus Production and Conjugation 
All viruses used in this study were generated by the University of Minnesota 
Viral Vector and Cloning Core except for virus used in electron microscopy. The 
experimental viral capsid AAV-DJ VP2-mMobA was prepared as previously 
described78. All viral genomes encoded miRFP670 under control of CAG promoter. 
The coding sequence for miRFP670 was a gift from Vladislav Verkhusha (Addgene 
plasmid # 79987 ; http://n2t.net/addgene:79987 ; RRID:Addgene_79987) 186. 
Immediately before injection, each virus was conjugated to appropriate antibody-
ssDNA. Virus was incubated at 37C for 45 minutes with 2mM MgCl2, 2 mM MnCl2, 
1:20 salmon sperm DNA, and excess antibody-ssDNA in PBS. After incubation, 
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each conjugation reaction was diluted to working volume in PBS and filtered 
through a 0.2-micron syringe filter. Conjugated viruses were kept on ice until 
injection into animals. 
 
Immunoelectron Microscopy 
Virus for electron microscopy was prepared by Vigene Biosciences from 
plasmid DNA encoding AAV-DJ VP2-mMobA, AAV-DJ VP2/3∆HBD, and pAAV-
HSV-TK. Virus was purified using IDX gradient ultracentrifugation to remove 
cellular contaminants and empty capsids. Prior to imaging, virus was reacted with 
a mouse CD3 antibody conjugated to the mMobA ssDNA sequence in HUH 
reaction conditions as described. The reaction was then incubated with an anti-
mouse 10 nm immunogold secondary antibody (Millipore Sigma) for 30 
minutes.  As a negative control, virus not conjugated to a primary antibody was 
incubated with the immunogold secondary antibody and imaged (data not shown). 
Transmission electron microscopy was performed by Wei Zhang in the University 
of Minnesota Characterization Facility. Antibody-virus was applied to charged 
carbon grids and negative stained with uranylformate. Samples were imaged using 
an FEI Tecnai T12 Transmission Electron Microscope. 
 
Animal Models 
All animal work was in accordance with a UMN Institutional Animal Care and 
Use Committee protocol. Xenografts were generated as previously described 178. 
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Briefly, athymic nude mice (Envigo) were subcutaneously injected with R1-
EnzRFAP cells, an immortalized prostate cancer cell line (CWR-R1-enzalutamide 
resistant/luciferase+) lentivirally transduced to express human FAP. Metastatic 
colony growth was monitored over 21 days leading up to virus injection. Antibody-
AAVs and appropriate controls were administered at a total volume of 100uL via 
tail vein injection. 
 
In Vivo Near-Infrared Imaging 
 miRFP670 and luciferase were imaged using an IVIS Spectrum In Vivo 
Imaging system with assistance of Guillermo Marques at the University of 
Minnesota- University Imaging Centers. Ten minutes prior to imaging, all animals 
were injected with D-luciferin. Images were collected 24-, 48-, 72-, 144-, 168-, and 
240-hours post-infection. After final imaging, animals were sacrificed. Liver, tumor, 





In the first experiment, all mice were infected with the αFAP-AAV infected at 
a multiplicity of infection (MOI) of approximately 3x1011 genome copies, which 
corresponds to approximately 1.5x1013 GC/kg, roughly one order of magnitude 
less than the standard AAV dosage for mice187. Mice were imaged seven days 
post-infection and harvested organs were imaged for miRFP expression 
immediately following sacrifice and harvest. Fluorescence was observed in the 
eyes of mice infected with αFAP-AAV, no antibody, and AAV-DJ. However, no 
fluorescence was observed in the eyes post-dissection (Figure 4.2b). Surprisingly, 
no fluorescence was visible in the liver of mice infected with AAV-DJ or αFAP-AAV 
(Figure 4.2c). In contrast to in vivo imaging, dissected tumor fluorescence was 
similar between AAV-DJ and αFAP-AAV (Figure 4.2c). In response to these data, 
we were interested in capturing how viral genome expression changed over time 
and determining whether αFAP-AAV would be effective at lower doses. 
In the second experiment, three MOIs of 2x1011(MOI 1), 2x1010(MOI 2), and 
2x109(MOI 3) were tested for the experimental αFAP-AAV group. All other viruses 
were administered at an MOI of 2x1011 GC/animal (8.6x1012 GC/kg). A time course 
of images at 48, 72, 144, 168, and 244 hours post-injection was collected to 
capture peak expression of miRFP670; expression was highest at the final time 
point when mouse tumors had grown large enough to necessitate sacrifice (Figure 
4.3a). It is possible that expression would have been higher after this time point. 
As a control, the same base capsid conjugated to αFAP was conjugated to a non-
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targeting IgG and administered at the highest dose (MOI 1). This group was added 
to test the idea that an interaction between an antibody and the tumor, not the 
antibody-antigen binding was facilitating infection. There was significant variability 
observed between animals in the same groups, particularly between the αFAP-
AAV-infected animals (Figure 4.3b). Animals infected with the IgG-AAV had higher 
expression of miRFP670 in the tumor than those infected with either AAV-DJ or 
the HUH-AAV without an antibody. However, αFAP-AAV provided the highest level 
of expression on the 10th day after injection (Figure 4.3c). The dynamics of 
miRFP670 expression were similar between treatment groups, with fluorescence 
slowly increasing over time and peaking at 240 hours for IgG-AAV and αFAP-AAV 
groups (Figure 4.3a). 
 
Immunoelectron microscopy 
Electron microscopy of the capsid revealed a very low percentage of capsids 
(3.8%) are conjugated to an antibody (Figure 4.4). Very few empty capsids were 
observed, meaning that capsid modification did not interfere with IDX gradient 
purification. Some gold particles were observed close to viral capsids in the 
negative control, suggesting that there is some rate of random association 
between the two. Further experiments will be necessary to calculate conjugation 
efficiency in optimized experimental conditions. 
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Discussions and Future Directions 
 
Initially, it appeared that addition of the anti-FAP antibody to the capsid of 
AAV strongly directed infection to the tumor via the FAP-antibody interaction. In 
the first set of experiments, the αFAP-AAV strikingly infected the tumor more 
efficiently than either the negative or positive control (Figure 4.2). It is unclear why 
there was no fluorescence observed in the liver of mice infected with AAV-DJ. 
AAV-DJ was selected specifically to be highly infective to the liver and evade 
preexisting antibodies 39. The reason for this is unclear but could be due to a 
number of factors including differences between mouse lines, as has been 
observed for other modified capsid variants. While there was some variability, it 
was clear from this experiment that αFAP-AAV infected the xenografted tumor 
more efficiently than any other treatment. 
Results from the second experiment introduced more concern about the 
mechanism of infection. Like the first experiment, αFAP-AAV infected the tumor 
more effectively than any other treatment at the same MOI (MOI 1). Infection 
dropped significantly at lower MOI, which is not entirely surprising (Figure 4.3b). 
10 days post-injection, he IgG-AAV infected the tumor more effectively than the 
base capsid not conjugated to any antibody. This suggests that there is some 
interaction between the tumor and either the IgG or αFAP antibody facilitating 
infection not via FAP antibody-antigen binding.  
The low antibody-AAV conjugation efficiency was not unexpected and can be 
attributed to several factors. First, the reaction efficiency of mMobA is maximally 
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around 50% when the recombinantly produced protein is assayed in excess 
ssDNA120. Producing the enzyme as a chimera with a viral protein likely decreases 
this efficiency, as does conjugating the ssDNA to an antibody. The reaction of an 
antibody-ssDNA and AAV-mMobA is much more sterically hindered. The ratio of 
modified VP2 incorporated in the capsid is unknown, and based on other VP2 
modification studies, is likely lower than the natural ratio (~three copies of VP2 per 
capsid) 17,44. These limiting aspects could be improved in future work by changing 
the HUH tag used and titrating VP2 expression levels by changing its promoter. 
Importantly, the conjugation rate is still measurable and clearly still results in viral 
capsids that can infect cells via the antibody-antigen interaction.  
With these data in mind, the titers reported in this study and in past work are 
not representative of the number of antibody-conjugated, infective particles 
present. It is likely that a purified antibody-AAV would be several orders of 
magnitude more infective than unmodified serotypes. The mixture we are currently 
administering is effectively 96.2% filler with only 3.8% active virus that can infect 
cells via the antibody-antigen interaction. A more effective virus could lead to lower 
injection volumes, lower production cost, and fewer off-target effects. Future work 






Experimental timeline for FAP+ prostate tumor targeting. Mice were 
subcutaneously injected with R1-EnzRFAP cells to implant a hind leg tumor. Three 
weeks after xenograft, αFAP-AAV was prepared and injected into the tail vein of 
each mouse. In the first experiment, mice were imaged and organs harvested 7 
days post-infection. Collected organs were imaged for miRFP670 expression. In 
the second experiment, mice were imaged at 48, 72, 144, 168, and 240 hours. At 





Analysis of mice seven days post-infection. A) Representative animal images 
from each experimental group. B) quantification of miRFP670 expression seven 




Analysis of infected mice over a ten-day time course. A) Average miRFP670 
expression measured as radiant efficiency 48, 72, 155, 168, and 240 hours after 
injection. B) Quantitation of miRFP670 expression 10 days post-infection C) 







Transmission electron microscopy images of antibody-AAV for calculation of 
conjugation efficiency. 6.4% of counted capsids were empty, 3.8% of capsids were 
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Adeno-associated virus has gained traction as a gene delivery vector in 
recent. However, its protein capsid remains largely uncharacterized. Using a 
domain insertion protocol recently developed by our lab (SPINE), we have begun 
a project to characterize AAV capsids with protein domains inserted at each 
position across all three capsid proteins (VP1-3) in two serotypes (AAV-DJ and 
AAV-2). While the results of this project are still outstanding, the work that has 
been completed so far is compiled here. The results of this project will provide 
information about the flexibility of the entire capsid and new candidate locations 
for insertion of functional domains. We also discuss the creation of a stable cell 





Recombinant adeno-associated virus (AAV) is a promising vector for clinical 
gene delivery because of its small size and relatively low immunogenicity 7. The 
two major challenges of using AAV in the clinic are its limited tropism and possible 
neutralization by preexisting antibodies 105,188. Efforts to rationally engineer the 
capsid of AAV to have better tissue specificity or to evade the immune system have 
been ongoing since the 1990s 40. While sometimes successful, directed mutations 
can prove a disastrous and tedious guess-and-check process 189. Saturating 
mutagenesis is more likely to identify a productive mutant, as all possible positions 
have been tested 190. In this work, we create a saturating domain insertion library 
from two serotypes of AAV to characterize capsid plasticity and locate regions 
permissible to functional domain insertion. 
AAV is a non-enveloped virus composed of a 25nm diameter protein capsid 
surrounding a single-stranded (ss)DNA genome 24. The protein capsid is made of 
three viral proteins named VP1, VP2, and VP3. The three proteins have 
overlapping coding sequences, with VP1 composed of the full 735 amino acid 
sequence, VP2 composed of amino acids 138-735, and VP3 composed of 203-
735 14,15. VP3 is the most abundant component of the 60-subunit capsid; the ratio 
of VP1:VP2:VP3 is reported to be 1:1:10 191,192. At the time of assembly, both 
termini of all three proteins are contained within the capsid itself, making it 
challenging to create terminally attached protein chimeras 25. Many viral protein 
engineering efforts for AAV focus on changing the tropism of the virus, typically 
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requiring the modified region to be readily displayed on the surface of the virus. 
This, combined with the fragility of the 60-mer, non-covalently assembled capsid 
has made directed engineering of AAV challenging.  
In place of structure-guided engineering, high-throughput approaches, such 
as directed evolution and in silico analyses to characterize and manipulate the 
capsid of AAV have been very well received in the last ten years 52–54,193. With 
increasingly accurate molecular imaging techniques such as cryo-EM, structural 
data is reaching a point of diminishing returns.  
Our lab has recently developed a method of inserting a protein domain at 
each amino acid across a protein of interest 194. This method is based on DNA 
synthesis, meaning that it is unbiased, unlike past library generation methods that 
relied upon transposase or DNase digests 195.  We wanted to use this method to 
interrogate the capsid of AAV, both to locate candidate regions for insertion of 
functional domains and to characterize permissibility of the capsid protein.  
We chose to start by preparing insertion libraries for two serotypes, AAV-2 
and AAV-DJ. AAV-DJ was selected from a shuffled capsid library of AAV-2, -4, -5, 
-8, and -9 to have high affinity for human hepatocytes and to be resistant to 
preexisting serum antibodies 39. AAV-2 and AAV-DJ differ in only 60 of 735 amino 
acids but have notably different bioactivity, making them interesting to compare. 
For the AAV-DJ library, we chose to mutate the heparin binding domain to yield a 
virus that is effectively non-infective in cell culture as previously shown 78. In the 
AAV-2 library, the heparin binding domain was left intact. All three viral protein start 
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codons were maintained in the AAV-2 library, meaning that an insertion would 
have to be tolerated in every protein of the viral capsid for a capsid to form and a 
genome to be packaged. In contrast, VP2 and VP3 start codons were mutated in 
the AAV-DJ library so only AAV-DJ VP1 would contain insertions. VP2 and VP3 
were supplied in trans for library production. VP1 is unique among capsid proteins 
because it contains a phospholipase domain necessary for endosomal escape and 
genome expression 36,102,196. Therefore, any capsid that results in productive 
infection can be assume to contain at least one copy of VP1.  
AAV functionality is a complex term that can be broken down into many steps. 
The capsid must be able to assemble, package a genome, be stable enough for 
collection, bind the surface of a cell for infection and be successfully endocytosed, 
escape the endosome, and deliver its genome to the nucleus to be expressed. We 
will test each of these steps separately through carefully designed assays. To test 
assembly, virus will be produced in HEK293 cells via transient transfection. After 
virus collection, genomes will be amplified and sequenced. Any variants that 
appear in this analysis can assemble into capsids stable enough for virus 
production and collection. We will test for cell binding and endocytosis using a 
previously described protocol197. To test for genome expression, we will use 
fluorescence-activated cell sorting to isolate cells expressing mKate2, which is co-
expressed with the VP library in the viral genome. We will then isolate and 
sequence genomes to determine which variants were collected. 
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One largely unaddressed problem in the field of AAV is the potential for cross-
packaging of variants. In AAV libraries, the genotype-phenotype linkage is 
maintained by a given capsid protein variant packaging its corresponding coding 
sequence in the ssDNA genome 135. Viral capsid assembly is stochastic and 
precedes genome packaging. If two variants are introduced to the same cell during 
production it is possible and likely that one protein variant would carry the ssDNA 
from the other. The way this has been addressed to this point is by lowering the 
amount of library plasmid DNA used to transfect packaging cells 117. While this 
reduces the number of cross-packaged variants, it is not perfect and significantly 
reduces the titer of virus produced.  
To address a similar problem of multiple library variants being expressed by 
a single transduced cell, the Fowler lab at the University of Washington has 
created a series of cell lines where expression is dependent upon integration 154. 
Only a single integration even can occur in any cell, meaning that each cell can be 
analyzed as a single variant of the library. We have designed a version of this cell 
line suitable for AAV library production (Figure 5.3). In this system, a library 
staging plasmid is used for preparation of the AAV library with the serotype and 
inserted domain of interest. Notably, this construct only contains the terminal 
inverted terminal repeat (ITR) and lacks a promoter. When transfected into a cell 
without an available corresponding genomic landing pad, neither an AAV genome 
nor any capsid protein will be expressed from this plasmid. Expression of the AAV 
library and corresponding genome are dependent upon integration to the 
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customized AAV library genomic landing pad. This landing pad is based directly 
on the pLenti-TetBxb1-BFP-iCasp9-Blast (LLP-iCasp9-Blast) cell line designed by 
the Fowler lab 154. Before integration of the AAV library from the staging plasmid, 
landing pad cells would express BFP and a synthetic form of Caspase 9 that 
causes cell death upon treatment with a small molecule (AP1903). The Caspase 
9-BFP coding region is removed upon recombination. Cells would be treated with 
AP1903 after transfection with AAV library to remove any cells that had not 
experienced recombination.  
In this system, as both AAV genome and capsid protein expression are 
dependent up on integration and there can be only one integrant per cell, we can 
assume perfect genotype-phenotype linkage. Helper plasmid and any required 
complementary viral protein plasmids could be transiently transfected into 
producer cells for viral library production. Because the iCasp9 system will have 
eliminated any nonintegrated cells, every cell can be assumed to be virus/variant-
producing. As AAV library creation continues to gain popularity, it may be useful to 
create this cell line to enable researchers to maintain stringent genotype-
phenotype linkages without the need for modified virus production conditions.  
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Methods & Materials 
OLS design  
Oligo pool sequences were designed as previously described using SPINE 
algorithm 195. Briefly, the coding sequences of AAV-DJ and AAV-2 were cloned 
into a pATT plasmid backbone and mutated to remove all BsaI and BsmBI sites. 
For AAV-DJ, the heparin binding domain (HBD) was mutated to an HA tag and the 
start codons for VP2 and VP3 (T138, M203, M211, and M235) were mutated. For 
AAV-2, all VP start codons and the HBD were left intact. The 735AA (2205nt) VP1 
CDS was divided into 14 fragments of 230 nucleotides each. At each nucleotide 
position, a pair of restriction sites was inserted in silico. For each fragment, unique 
subpool amplification barcodes were added to the ends. All AAV-DJ sequences 
were ordered pooled with several other libraries; AAV-2 sequences were similarly 
ordered at a later date. 
 
Library preparation and validation 
For each of the 14 fragments, backbone was amplified around the 230nt 
section used for the oligo pool. Oligo pool fragments were amplified using primers 
that bound to their subpool amplification identifying barcodes. All amplified 
products were purified on an agarose gel. The backbone and oligo for each 
fragment was assembled via 42-cycle Golden Gate reaction. Assembled reactions 
were digested with DpnI and PlasmidSafe (Lucigen) to remove contaminating 
template DNA. After digestion, each reaction was electroporated into competent 
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cells. Three dilutions were plated on antibiotic plates, and remaining transformed 
cells were expanded for 16 hours in 20 mL of media. Cells were pelleted and 
plasmid DNA was extracted using a miniprep kit (Zymo). At this point, an equimolar 
amount of DNA from each fragment was combined, and a sample was sent for 
NovaSeq sequencing to confirm equal coverage. Analytical digests and PCR were 
performed to interrogate coverage as well.  
 After pooling all fragments, the genetic handle was replaced with a 
chloramphenicol cassette using the same Golden Gate assembly workflow. 
Transformed cells were plated on ampicillin/chloramphenicol double antibiotic 
plates. This was done to remove contaminating non-library plasmid DNA. Plasmid 
DNA was prepared and the chloramphenicol cassette was replaced with the coding 
sequence for an anti-GFP nanobody via Golden Gate assembly. Finally, the 
nanobody-containing VP1 ORF was cloned into a plasmid backbone containing 
ITRs, a CMV promoter, and mKate2. At this point, another aliquot of the plasmid 
library was sent for NovaSeq S1 2x150bp sequencing. 
 
Viral library generation 
Prepared plasmid DNA for the VP1 library, a construct containing AAV2 rep 
promoter and VP2/3 ∆HBD-HA, and pHelper were transfected into 60% confluent 
HEK293-AAV cells. Cells were transfected using an established protocol for AAV 
library capsid production to minimize cross-packaging between variants 117. 72 
hours after transfection, cells were harvested and lysed using freeze/thaw cycles.  
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GFP affinity pulldown 
 GFP beads were prepared as previously described 78. Briefly, GFP with a 
free C-terminal cysteine was recombinantly produced in E. coli and purified via 
Histidine affinity resin. Biotin-maleimide was conjugated to purified GFP protein to 
create biotin-GFP. Streptavidin magnetic beads (NEB) were incubated with excess 
biotin-GFP to create GFP beads. Excess GFP-biotin was removed by washes with 
low-salt buffer. 
AAV-containing lysate was bound to GFP beads. Beads were pelleted using 
a magnet and supernatant was collected. GFP-beads were then washed three 
times with low-salt buffer to remove any weak non-GFP/nanobody interactions. 
After washing, beads were resuspended in PBS and treated with Benzonase 
(Sigma Aldrich), then proteinase to liberate viral genomes from bound capsids. 
Genomes were purified using a ssDNA clean-up kit (Zymo) and frozen a -20 for 
future sequencing.  
 
Cloning for stable cell line 
 Plasmids pLenti-TetBxb1-BFP-2A-iCasp9-Blast(LLP-iCasp9-Blast) and 
AttB-EGFP(700) were a generous gift from Douglas Fowler’s lab 154. To prepare a 
staging construct for AAV libraries, a P2A site, mKate2, a poly adenylation signal, 
and a single ITR were cloned into pAttB_EGFP, replacing the eGFP. To prepare 
a lentiviral genome for creation of a cell line with an AAV landing pad, a single ITR 
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was cloned into pLenti-TetBxb1-BFP-2A-iCasp9-Blast(LLP-iCasp9-Blast) 
between the first LTR and Tet promoter. These plasmids have been sequenced 
and stored for future use. 
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Results, Discussion and Future Directions 
 
This project is still ongoing and few results can be reported at this time. 
OLS-mediated library generation of AAV-DJ VP1 and AAV-2 VP1/2/3 has been 
completed. From sequencing and digest analysis, the AAV-DJ VP1 library is 
minimally biased and has good coverage across all fragments (Figure 5.2a, 5.2b). 
This diversity was maintained through multiple cloning steps to the pAAV 
backbone used for virus production (Figure 5.2c). The AAV-2 library is currently 
being made and validated. The next step will be selecting new domains to test and 
performing functional assays on multiple domain insertion libraries. As 
aforementioned, we will test the library at each step throughout the production and 
infection process to characterize what impact insertion of each domain at each 
location has on the capsid. In the past, we have identified site/domain 
combinations that result in production of a capsid stable enough for collection and 
function of the domain, but interfere with infectivity. It is likely that modified capsid 
properties are determined by the unique combination of domain and insertion site, 
making it challenging to predict which combinations will produce a functional 
capsid without more experimental data. 
Once this project is complete, we aim to have identified multiple sites on the 
capsid that are suitable for incorporation of new functional moieties, i.e. a site for 
an affinity tag that is compatible with VR-IV HUH tag insertion. Incorporation of 
new domains will increase the complexity of functions that can be performed by 
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the capsid; it could be possible to make an environment-sensitive capsid that is 
only infective within a specific tumor microenvironment201, 202. Increasing the 
complexity of AAV capsid function will result in more specific, safer delivery 
vectors203. 
Constructs for the AAV landing pad stable cell line have been prepared and 
are ready to be used to make lentivirus for cell line creation. Depending upon how 
much interest there is in AAV library approaches, this cell line could be worth 
producing in the future. One potential issue we could face is the efficiency of library 
production from a single genomic locus. In standard recombinant AAV production, 
viral proteins and genome are produced from multiple copies of plasmid DNA 
transfected into the cell. If expression is dependent upon genomic integration, all 
viral proteins and genomes will be expressed from that single locus. This is not 
dissimilar from how the natural virus is expressed from its integrated genome204. I 
hypothesize that proteins will also be expressed from free viral genome once it has 
been produced, making high-titer production likely. If viral production is too low in 









Workflow for creation of an AAV insertional scanning library. Initially, the 
library was assembled from the amplified oligo pool and VP1 in pATT staging 
backbone with a genetic handle as the inserted domain. The genetic handle was 
then exchanged for a chloramphenicol resistance cassette. The chloramphenicol 
cassette was then exchanged for the domain of interest, in this case, the anti-GFP 
nanobody. The VP1 CDS was then moved into an expression plasmid backbone 




Analysis of AAV-DJ insertional library throughout generation. A) Analytical 
digest and PCR of fragments 1-14 of AAV-DJ VP1 insertional library in pATT 
backbone with genetic handle insert. B) Sequencing results from AAV-DJ VP1 
library in pATT backbone with genetic handle insert, confirming results of a. c) 






Design of a stable cell line for AAV library production without cross-






Conclusion & Future Directions 
 
 
AAV-antibody conjugate engineering 
I have created a modular system of attaching a targeting moiety to the capsid 
of AAV using a combination of protein engineering and chemical conjugation. 
These conjugates are effectively retargeted to infect cells via an antibody-antigen 
(or similar) interaction, losing natural tropism in favor of user-defined tropism. This 
addresses a long-time problem in the field and is a promising method of delivering 
genes specifically and to previously inaccessible targets. Future work will improve 
purification of antibody-conjugated capsids to produce a cleaner, better-
characterized product. Conjugation efficiency could also be improved by testing 
different HUH tags, changing the ratio of modified protein to complementary capsid 
proteins, and changing reaction conditions. 
I have also demonstrated that the variable region IV loop is a suitable location 
for nanobody and Gp2 insertion in VP1, VP2, and VP3. This is the first reported 
positon other than the heparin binding domain that can be modified across all three 
capsid proteins. All six of these modified capsids infected cells expressing their 
targeted antigen specifically and efficiently in culture. In the future, these 
constructs could serve as basis for inserting a targeting scaffold library into the 
capsid at the same position, and selecting for a tissue-specific variant in vivo. This 
project would be very similar to the work completed by the Gradinaru group where 
variants that effectively crossed the blood-brain-barrier were selected from a library 
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of capsids with a 7-amino acid diversified region 46,193. Importantly, however, 
because existing AAV infectivity has been removed in our context, the selected 
targeting variant would be responsible for tissue binding. This means that the 
selected variant could be expressed independently from the capsid for biophysical 
characterization. This technique could be an update to current methods used for 
affinity selection, such as phage display or yeast display, and would account for 
the environment in which a targeting moiety is more likely to be used.  
 
AAV-delivered prime editor 
 I assisted with creation and testing of an AAV-compatible version of prime 
editor. Editing rates are still low, and it will be important to demonstrate effective 
delivery using AAV in different contexts including primary cells and in vivo. It is 
worth noting that unmodified prime editor has been reported to have extremely 
variable efficiency, which seems to depend largely on editing context 172. As prime 
editor guide design improves for s. pyogenes prime editor, it should provide 
information for how to improve editing efficiencies for s. aureus as well. The 
flexibility of prime editor makes it a candidate for treatment of many genetic 
disorders. 
 New editing tools are created at a breakneck pace, and it can be difficult to 
know which ones represent useful innovation. At this moment, safe, effective 
delivery is the main hurdle facing clinical gene editing, whether that delivery occurs 
in vivo or ex vivo59. Past editing tools have uniformly followed a path from initial 
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discovery, to modification for packaging in a delivery vector, to delivery in 
vivo64,65,156. Given this history, adapting prime editor for AAV-mediated delivery 
was the clear next step in bringing the technology one step closer to clinical trials. 
 
Prostate tumor targeting 
In this work, I demonstrated that the antibody-AAV technology described in 
my first paper can be safely and effectively used in vivo. While this data is still 
preliminary and will require further replication, it is a promising first step. The ability 
to deliver both a therapeutic effector (i.e. HSV-TK) and an imaging tool 
(miRFP670) fulfills the promise of creating effective, modern combination 
therapeutic/diagnostics. EM imaging of the capsid reinforces the belief that, while 
the vector is effective in its current state, further purification will be important to 
creating a maximally efficient gene delivery tool. 
Cancer gene therapy using a targeted delivery vector is an important step 
towards safe and efficacious treatment. Many cancer-associated antigens have 
been described that are good targets for future development of antibody-directed 
gene delivery vectors 177,198. In the future, we are interested in using the HUH-AAV 
technology to target other types of tumors, particularly in cancers where surgical 
removal is not an option. It would also be interesting to pursue in vivo generation 
of immunotherapy agents such as chimeric antigen receptors (CARs)199. In my 
mind, the clear next target for antibody-AAV mediated infection is bone marrow 
and blood cells, particularly CD34+ hematopoietic stem cells (HSCs). Delivery of 
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editing reagents specifically to HSCs represents a huge therapeutic potential for 
treatment of rare genetic blood and immune disorders (i.e. sickle cell disease, 
severe combined immunodeficiency) 60,200. Whether this technology or another is 
used to achieve targeted delivery, gene therapy and/or editing for these disorders 
is incredibly promising. 
 
Domain insertion library of AAV 
This project is still in very early stages, and much of the data is yet to be 
collected. Thus far, I have prepared or assisted in preparation of domain insertion 
libraries for AAV-DJ and AAV-2. Libraries have been deep-sequenced and 
confirmed to be relatively unbiased. For this project, it will be important to analyze 
the insertion profile of many domains across the VP1 open reading frame. After 
collecting data for these two serotypes, we will investigate other AAV serotypes. 
In the future, this approach could be applied to other viral capsids and large 
multimeric proteins. 
My design for an AAV library production stable cell line could be pursued by 
myself or others in the future to improve the fidelity of library genotype-phenotype 
linkage. The prevalence of cross-packaging in AAV libraries is a problem that has 
been minimally investigated, partially because it can be difficult to measure and 
partially because existing methods can select successful variants. It will be 
important to further characterize rates of cross-packaging for ideal AAV library 
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